fenofibrate has been researched along with Dyslipidemias in 229 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We performed the first ever network meta-analysis containing the largest ever group of patients to test the efficacy of pemafibrate in improving lipid levels compared with fenofibrate and placebo in patients with dyslipidemia." | 9.41 | Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review. ( Ali, SS; Aziz, M; Baqi, A; Ghumman, GM; Katragadda, S; Khan, MS; Mir, T; Shah, J; Singh, H; Tahir, A; Taleb, M, 2023) |
| "The STAFENO trial is a prospective, randomized, open-label, multi-center trial to compare the effect of statin plus fenofibrate with statin alone on the reduction and stabilization of plaque in non-diabetic, combined dyslipidemia patients with non-intervened, intermediate coronary artery disease (CAD) using virtual histology-intravascular ultrasound at 12 months." | 9.34 | Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFE ( Bae, JH; Han, SH; Hong, YJ; Jang, AY; Kim, SH; Kim, SW; Kwon, TG; Lee, SY, 2020) |
| "In these Korean patients with mixed dyslipidemia and a high risk for CVD, combination therapy with pitavastatin/fenofibrate was associated with a greater reduction in non-HDL-C compared with that with pitavastatin monotherapy, and a significantly improvement in other lipid levels." | 9.34 | Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial. ( Chae, IH; Cho, BR; Cho, HC; Chung, CH; Chung, WB; Han, KA; Her, SH; Hwang, BH; Ihm, SH; Jeon, DW; Kang, SH; Kim, HJ; Kim, HS; Kim, JH; Lee, BW; Lee, JB; Lee, JM; Park, SD; Park, TH; Seung, KB; Song, WH; Won, KH; Woo, JT; Yoo, KD; Yu, JM, 2020) |
| " This controlled, randomized clinical trial was designed to compare the efficacy and safety of fenofibrate, policosanol and a combination of these 2 in lowering low-density-lipoprotein cholesterol (LDL-C) in elderly patients with mixed dyslipidemia." | 9.27 | Efficacy and Safety of Policosanol Plus Fenofibrate Combination Therapy in Elderly Patients with Mixed Dyslipidemia: A Randomized, Controlled Clinical Study. ( Chen, SY; Fang, NY; Jiang, H; Jiao, QP; Lu, J; Sheng, J; Wang, HY; Zheng, SB, 2018) |
| "FDC fenofibrate/simvastatin are effective and well-tolerated therapies to improve the TG and HDLC profile in high-risk patients with mixed dyslipidemia." | 9.20 | New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies. ( Aubonnet, P; Belenky, D; Berli, M; Calvo Vargas, CG; Foucher, C; Koch, HF; Lochocka, A; Reichert, P; Schaeffer, A, 2015) |
| "Alternate day therapy with atorvastatin-fenofibrate combination is an effective and safe alternative to daily therapy in mixed dyslipidemia." | 9.19 | Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial. ( David, DC; Haribalaji, N; Harivenkatesh, N; Sudhakar, MK, 2014) |
| " Patients (N = 100) with mixed dyslipidemia on a standard statin dose (10-40 mg simvastatin or 10-20 mg atorvastatin or 5-10 mg rosuvastatin) who had not achieved lipid targets were randomized to switch to the highest dose of rosuvastatin (40 mg/day) or to add-on-statin extended release nicotinic acid (ER-NA)/laropiprant (LRPT) (1000/20 mg/day for the first 4 weeks followed by 2000/40 mg/day for the next 8 weeks) or to add-on-statin micronized fenofibrate (200 mg/day) for a total of 3 months." | 9.19 | Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia. ( Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A, 2014) |
| "To assess whether adding a fibrate to statin therapy reduces residual cardiovascular risk associated with elevated triglycerides and low high-density lipoprotein cholesterol, The Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) trial evaluated the effects of fenofibric acid (FA) treatment on cIMT in patients with mixed dyslipidemia on atorvastatin." | 9.19 | Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). ( Ballantyne, CM; Camp, HS; Carlson, DM; Davidson, MH; Kelly, MT; Lele, A; Maki, KC; Mazzone, T; Nicholls, SJ; Rosenson, RS; Stolzenbach, JC; Williams, LA, 2014) |
| "The efficacy and safety of combination therapy with rosuvastatin + fenofibric acid were demonstrated in a 12-week controlled study (NCT00300482) of patients with mixed dyslipidemia who were randomized to rosuvastatin 10, 20, or 40 mg, fenofibric acid 135 mg, or rosuvastatin 10 or 20 mg + fenofibric acid 135 mg." | 9.16 | One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. ( Davidson, MH; Ferdinand, KC; Kelly, MT; Setze, CM, 2012) |
| "In this analysis of patients with mixed dyslipidemia, the lipid effects of ezetimibe plus fenofibrate were generally similar in metabolic syndrome patients versus those without metabolic syndrome." | 9.15 | Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome. ( Bays, HE; Gumbiner, B; Macdonell, G; Shah, A; Taggart, WV, 2011) |
| "A combination of fenofibrate and niacin with low-saturated-fat D/E is effective and safe in increasing HDL-C, decreasing non-HDL-C and hypertriglyceridemia, and ameliorating hypoadiponectinemia in patients with HIV/ART-associated dyslipidemia." | 9.15 | Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. ( Balasubramanyam, A; Ballantyne, CM; Clark, P; Coraza, I; Cuevas-Sanchez, E; Giordano, TP; Iyer, D; Kamble, S; Patel, P; Pownall, HJ; Scott, LW; Sekhar, RV; Smith, EO; Taylor, AA, 2011) |
| "We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 9.14 | Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( D'Emden, M; Ehnholm, C; Fulcher, G; Keech, A; O'Brien, R; Pardy, C; Scott, R; Taskinen, MR; Tse, D, 2009) |
| "To evaluate a new formulation of fenofibric acid (ABT-335) co-administered with 2 doses of rosuvastatin in patients with mixed dyslipidemia." | 9.14 | Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. ( Buttler, SM; Davidson, MH; Jones, PH; Kashyap, ML; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2009) |
| " A total of 657 patients with mixed dyslipidemia (low-density lipoprotein cholesterol [LDL-C] > or =130 mg/dL, triglycerides [TGs] > or =150 mg/dL, and high-density lipoprotein cholesterol [HDL-C]<40 mg/dL [men] or <50 mg/dL [women]) were randomized to 12 weeks of treatment with ABT-335 + simvastatin (20 or 40 mg) combination therapy, ABT-335 monotherapy (135 mg), or simvastatin monotherapy (20, 40, or 80 mg)." | 9.14 | Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. ( Buttler, SM; Kelly, MT; Mohiuddin, SM; Pepine, CJ; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2009) |
| "OBJECTIVE To compare the effect of short-term metformin and fenofibrate treatment, administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors, and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia." | 9.14 | Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. ( Krysiak, R; Okopien, B; Pruski, M, 2009) |
| "This trial compares the efficacy of administering a combination of ezetimibe plus fenofibrate as an alternative to statin monotherapy for the treatment of dyslipidemia." | 9.14 | Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. ( Day, A; Kumar, SS; LaHaye, SA; Lahey, KA, 2009) |
| "Coadministration of statin and fenofibrate monotherapies is frequently used to treat patients with dyslipidemia; however, a fixed-dose combination (FDC) tablet is not currently marketed." | 9.14 | Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. ( Beckert, M; Davidson, MH; Drucker, J; Eugene Griffin, H; Oosman, S; Rooney, MW, 2009) |
| "We prospectively compared the anti-inflammatory and antidyslipidemic effects of fenofibrate and statins in rheumatoid arthritis (RA) patients." | 9.14 | A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. ( Goto, M, 2010) |
| "To compare fenofibric acid (FA) + statin to respective monotherapies on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia." | 9.14 | The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia. ( Bays, HE; Kelly, MT; McKenney, JM; Obermeyer, K; Roth, EM; Setze, CM; Sleep, DJ; Thakker, KM, 2010) |
| "Statin and ezetimibe combination therapy may be insufficient to improve lipid and nonlipid parameters beyond low-density lipoprotein cholesterol (LDL-C) in patients with mixed dyslipidemia." | 9.14 | Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. ( Goldberg, AC; Jones, PH; Kelly, MT; Knapp, HR; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2010) |
| "In conclusion, rosuvastatin 5 mg + fenofibric acid 135 mg resulted in comprehensive improvements in the lipid profile of patients with mixed dyslipidemia without unanticipated adverse events." | 9.14 | Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. ( Blasetto, JW; Carlson, DM; Fukumoto, SM; Khurmi, NS; Rosenson, RS; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA, 2010) |
| "The combination of rosuvastatin and fenofibric acid (R + FA) results in more comprehensive lipid improvements than corresponding-dose monotherapies, without additional safety concerns, in elderly patients with mixed dyslipidemia." | 9.14 | Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. ( Carlson, DM; Gold, A; Jacobson, TA; Kelly, MT; Pepine, CJ; Setze, CM; Stolzenbach, JC; Williams, LA, 2010) |
| "To estimate the effects of 4-weeks therapy of micronized fenofibrate in dose 267 mg/d on C-reactive protein (CRP), fibrinogen, thiobarbituric acid reaction substances (TBARS) concentrations in isolated erythrocyte membranes and the activities of antioxidants enzymes such: catalase (CAT), glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) in erythrocytes in patients with visceral obesity and atherogenic dyslipidemia." | 9.12 | [The anti-inflammatory and antioxidants effects of micronized fenofibrate in patients with visceral obesity and dyslipidemia]. ( Broncel, M; Chojnowska-Jezierska, J; Cieślak, D; Duchnowicz, P; Koter-Michalak, M; Mackiewicz, K, 2006) |
| "To compare the efficacy of pemafibrate (PF) and fenofibrate (FF) in treating dyslipidemia." | 9.01 | Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate. ( Li, H; Liu, J; Wang, F; Wang, H; Zhao, Q; Zhou, Y, 2019) |
| "The authors review current literature on the use of fenofibrate and related derivatives in HIV-infected people with dyslipidemia using antiretroviral therapy." | 8.86 | Fenofibrate in the treatment of dyslipidemia associated with HIV infection. ( Fichtenbaum, CJ; Samineni, D, 2010) |
| " Because of concomitant atherogenic dyslipidemia, all patients were treated with fenofibrate (200 mg daily) for 12 weeks." | 7.91 | Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia. ( Krysiak, R; Okopień, B; Szkróbka, W, 2019) |
| "The study included 36 premenopausal women with mixed dyslipidemia and slightly increased prolactin levels, 17 of whom had already been treated with bromocriptine (5." | 7.83 | The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study. ( Krysiak, R; Okopień, B; Okrzesik, J; Szkrobka, W, 2016) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 7.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| "The study included three age-, weight-, and lipid-matched groups of older men with atherogenic dyslipidemia and late-onset hypogonadism, treated with oral testosterone undecanoate (120 mg daily, n = 15), micronized fenofibrate (200 mg daily, n = 15), or testosterone plus fenofibrate (n = 18)." | 7.81 | The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia. ( Gilowski, W; Krysiak, R; Okopien, B, 2015) |
| "Ursodeoxycholic acid (UDCA) is currently the only available pharmacological treatment for asymptomatic primary biliary cirrhosis (aPBC)." | 7.79 | Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis. ( Dohmen, K; Haruno, M; Tanaka, H, 2013) |
| "Fenofibrate therapy reduces serum triglycerides (TG) and increases high-density lipoprotein-cholesterol (HDL-C) and thus addresses the atherogenic dyslipidemia associated with metabolic syndrome (MetS)." | 7.77 | Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status. ( An, P; Arnett, DK; Borecki, IB; Feitosa, MF; Hopkins, PN; Ketkar, S; Ordovas, JM; Straka, RJ, 2011) |
| "Fenofibric acid + statin combination therapy in patients with mixed dyslipidemia and type 2 diabetes was well tolerated and resulted in more comprehensive improvement in the lipid/apolipoprotein profile than either monotherapy." | 7.76 | Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. ( Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K, 2010) |
| "To compare the effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation with the standard 160-mg tablet in patients with dyslipidemia and coronary heart disease." | 7.74 | Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia. ( Hilleman, D; Maciejewski, S, 2008) |
| "We describe one patient with diabetes mellitus treated by fenofibrate monotherapy since several years; 48 h after gliclazide therapy was introduced, rhabdomyolysis occurred." | 7.73 | [Rhabdomyolysis induced by fenofibrate monotherapy]. ( Amaniou, M; Archambeaud-Mouveroux, F; Combes, C; Galinat, S; Lassandre, S; Lopez, S; Teissier, MP, 2006) |
| "To compare the effect of high-dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on the lipoprotein subfraction profile in patients with mixed dyslipidaemia and MetS." | 6.77 | Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. ( Agouridis, AP; Bairaktari, ET; Elisaf, MS; Kostapanos, MS; Kostara, C; Mikhailidis, DP; Tselepis, AD; Tsimihodimos, V, 2012) |
| " In conclusion, these data suggest that a combination of fenofibric acid and a statin could be considered safe and efficacious for treating women with mixed dyslipidemia." | 6.76 | Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia. ( Bittner, V; Goldberg, AC; Kelly, MT; Lele, A; Pepine, CJ; Setze, CM; Sleep, DJ; Thakker, K, 2011) |
| " This multicenter, double-blind, active-controlled study evaluated ABT-335 (fenofibric acid) in combination with 2 doses of atorvastatin in patients with mixed dyslipidemia." | 6.74 | Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. ( Ballantyne, CM; Bays, HE; Buttler, SM; Goldberg, AC; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2009) |
| "Patients with type 2 diabetes mellitus and no histories of coronary heart disease were evaluated (n = 498)." | 6.73 | Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). ( Anderson, JL; Horne, BD; Jensen, JR; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Yannicelli, HD, 2008) |
| "Dyslipidemia is one of the major cardiovascular risk factors, but beyond statin treatment-which represents the cornerstone of therapy-a relevant practical uncertainty regards the use of fibrate derivatives." | 6.58 | Fenofibrate and Dyslipidemia: Still a Place in Therapy? ( Brunetti, ND; Correale, M; De Gennaro, L; Di Biase, M; Romano, S; Santoro, F; Tarantino, N, 2018) |
| "Fenofibrate is a fibric acid derivative with lipid-modifying effects that are mediated by the activation of peroxisome proliferator-activated receptor-α." | 6.47 | Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. ( Keating, GM, 2011) |
| " The fibrate class of drugs has proven efficacy in improving secondary targets; however, concerns regarding severe myopathy and rhabdomyolysis have limited their combination with statins." | 6.46 | Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid. ( Hilleman, DE; Maciejewski, SR; Mohiuddin, SM; Schima, SM; Williams, MA, 2010) |
| " It has been extensively evaluated both as monotherapy and in combination with atorvastatin, rosuvastatin, and simvastatin in a large number of patients with mixed dyslipidemia for up to 2 years and appears to be a safe and effective option in the management of dyslipidemia." | 6.46 | Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. ( Elisaf, MS; Kei, A; Milionis, HJ; Moutzouri, E, 2010) |
| "Dyslipidemia is an important modifiable risk factor." | 6.46 | The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes. ( Campbell, J; Mohiuddin, SM, 2010) |
| "Mixed dyslipidemia is a common lipid disorder characterized by the presence of an atherogenic lipoprotein phenotype due to abnormalities in various atherogenic and anti-atherogenic lipoproteins." | 6.44 | Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. ( Farnier, M, 2008) |
| "Fenofibrate is a fibric acid derivative indicated for use in the treatment of primary hypercholesterolaemia, mixed dyslipidaemia and hypertriglyceridaemia in adults who have not responded to nonpharmacological measures." | 6.44 | Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. ( Croom, KF; Keating, GM, 2007) |
| " We performed the first ever network meta-analysis containing the largest ever group of patients to test the efficacy of pemafibrate in improving lipid levels compared with fenofibrate and placebo in patients with dyslipidemia." | 5.41 | Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review. ( Ali, SS; Aziz, M; Baqi, A; Ghumman, GM; Katragadda, S; Khan, MS; Mir, T; Shah, J; Singh, H; Tahir, A; Taleb, M, 2023) |
| "Subclinical hypothyroidism is suggested to increase cardiovascular risk." | 5.40 | Different effects of fenofibrate on metabolic and cardiovascular risk factors in mixed dyslipidemic women with normal thyroid function and subclinical hypothyroidism. ( Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W, 2014) |
| " Once-daily fenofibric acid 135 mg plus a statin was generally as well tolerated as monotherapy with fenofibric acid 135 mg/day or the corresponding statin dosage in the three phase III trials in patients with mixed dyslipidemia." | 5.35 | Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia. ( Keating, GM; Yang, LP, 2009) |
| "The STAFENO trial is a prospective, randomized, open-label, multi-center trial to compare the effect of statin plus fenofibrate with statin alone on the reduction and stabilization of plaque in non-diabetic, combined dyslipidemia patients with non-intervened, intermediate coronary artery disease (CAD) using virtual histology-intravascular ultrasound at 12 months." | 5.34 | Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFE ( Bae, JH; Han, SH; Hong, YJ; Jang, AY; Kim, SH; Kim, SW; Kwon, TG; Lee, SY, 2020) |
| "In these Korean patients with mixed dyslipidemia and a high risk for CVD, combination therapy with pitavastatin/fenofibrate was associated with a greater reduction in non-HDL-C compared with that with pitavastatin monotherapy, and a significantly improvement in other lipid levels." | 5.34 | Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial. ( Chae, IH; Cho, BR; Cho, HC; Chung, CH; Chung, WB; Han, KA; Her, SH; Hwang, BH; Ihm, SH; Jeon, DW; Kang, SH; Kim, HJ; Kim, HS; Kim, JH; Lee, BW; Lee, JB; Lee, JM; Park, SD; Park, TH; Seung, KB; Song, WH; Won, KH; Woo, JT; Yoo, KD; Yu, JM, 2020) |
| " This controlled, randomized clinical trial was designed to compare the efficacy and safety of fenofibrate, policosanol and a combination of these 2 in lowering low-density-lipoprotein cholesterol (LDL-C) in elderly patients with mixed dyslipidemia." | 5.27 | Efficacy and Safety of Policosanol Plus Fenofibrate Combination Therapy in Elderly Patients with Mixed Dyslipidemia: A Randomized, Controlled Clinical Study. ( Chen, SY; Fang, NY; Jiang, H; Jiao, QP; Lu, J; Sheng, J; Wang, HY; Zheng, SB, 2018) |
| "This study investigated whether the beneficial effects of intensive glycemic control and fenofibrate treatment of dyslipidemia in reducing retinopathy progression demonstrated in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study persisted beyond the clinical trial." | 5.22 | Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. ( , 2016) |
| " The objective of this study was to evaluate the efficacy and safety profile of fenofibrate as an add-on in patients with dyslipidemia despite receiving statin therapy." | 5.22 | Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment. ( Chen, H; Cheng, X; Cui, S; Dai, Y; Dong, Y; Fu, G; Gong, H; Hu, T; Huang, H; Li, X; Li, Z; Liao, Y; Lin, L; Liu, J; Liu, X; Sun, Y; Tong, Q; Wang, D; Wang, F; Wang, G; Wei, P; Xie, Q; Yan, J; Yan, L; Yan, Y; Yin, Y; Zhao, S, 2016) |
| "FDC fenofibrate/simvastatin are effective and well-tolerated therapies to improve the TG and HDLC profile in high-risk patients with mixed dyslipidemia." | 5.20 | New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies. ( Aubonnet, P; Belenky, D; Berli, M; Calvo Vargas, CG; Foucher, C; Koch, HF; Lochocka, A; Reichert, P; Schaeffer, A, 2015) |
| "Fenofibrate is a peroxisome proliferator-activated receptor-α that has been clinically used to treat dyslipidemia and insulin resistance." | 5.19 | Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue. ( Chen, M; Deng, D; Fang, Z; Hu, H; Luo, L; Wang, Y; Xu, M, 2014) |
| "Alternate day therapy with atorvastatin-fenofibrate combination is an effective and safe alternative to daily therapy in mixed dyslipidemia." | 5.19 | Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial. ( David, DC; Haribalaji, N; Harivenkatesh, N; Sudhakar, MK, 2014) |
| " Patients (N = 100) with mixed dyslipidemia on a standard statin dose (10-40 mg simvastatin or 10-20 mg atorvastatin or 5-10 mg rosuvastatin) who had not achieved lipid targets were randomized to switch to the highest dose of rosuvastatin (40 mg/day) or to add-on-statin extended release nicotinic acid (ER-NA)/laropiprant (LRPT) (1000/20 mg/day for the first 4 weeks followed by 2000/40 mg/day for the next 8 weeks) or to add-on-statin micronized fenofibrate (200 mg/day) for a total of 3 months." | 5.19 | Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia. ( Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A, 2014) |
| "To assess whether adding a fibrate to statin therapy reduces residual cardiovascular risk associated with elevated triglycerides and low high-density lipoprotein cholesterol, The Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) trial evaluated the effects of fenofibric acid (FA) treatment on cIMT in patients with mixed dyslipidemia on atorvastatin." | 5.19 | Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). ( Ballantyne, CM; Camp, HS; Carlson, DM; Davidson, MH; Kelly, MT; Lele, A; Maki, KC; Mazzone, T; Nicholls, SJ; Rosenson, RS; Stolzenbach, JC; Williams, LA, 2014) |
| "This multicenter, randomized study evaluated the short-term efficacy and safety profile of fenofibric acid (FA) + rosuvastatin (R) combination therapy for improving lipid parameters in patients with stage 3 CKD and mixed dyslipidemia." | 5.17 | A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease. ( Burns, KM; Carlson, DM; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Weinstein, DL; Williams, LA, 2013) |
| " In this study, mixed dyslipidemia patients (n = 100) inadequately controlled with a standard statin dose were randomized to switch to 40 mg of rosuvastatin or add-on extended release nicotinic acid/laropiprant (ER-NA/LRPT) or add-on fenofibrate." | 5.17 | Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions. ( Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A, 2013) |
| "The efficacy and safety of combination therapy with rosuvastatin + fenofibric acid were demonstrated in a 12-week controlled study (NCT00300482) of patients with mixed dyslipidemia who were randomized to rosuvastatin 10, 20, or 40 mg, fenofibric acid 135 mg, or rosuvastatin 10 or 20 mg + fenofibric acid 135 mg." | 5.16 | One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. ( Davidson, MH; Ferdinand, KC; Kelly, MT; Setze, CM, 2012) |
| "We randomly allocated 60 patients with mixed dyslipidemia (low-density lipoprotein cholesterol: >160 mg/dL plus triglycerides: >200 mg/dL) to receive rosuvastatin 40 mg (n = 22), rosuvastatin 10 mg plus fenofibrate 200 mg (n = 21), or rosuvastatin 10 mg plus omega-3 fatty acids 2 g (n = 17) daily for 3 months." | 5.16 | Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels. ( Agouridis, AP; Challa, A; Elisaf, M; Liberopoulos, EN; Makariou, SE, 2012) |
| "In this analysis of patients with mixed dyslipidemia, the lipid effects of ezetimibe plus fenofibrate were generally similar in metabolic syndrome patients versus those without metabolic syndrome." | 5.15 | Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome. ( Bays, HE; Gumbiner, B; Macdonell, G; Shah, A; Taggart, WV, 2011) |
| "A combination of fenofibrate and niacin with low-saturated-fat D/E is effective and safe in increasing HDL-C, decreasing non-HDL-C and hypertriglyceridemia, and ameliorating hypoadiponectinemia in patients with HIV/ART-associated dyslipidemia." | 5.15 | Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. ( Balasubramanyam, A; Ballantyne, CM; Clark, P; Coraza, I; Cuevas-Sanchez, E; Giordano, TP; Iyer, D; Kamble, S; Patel, P; Pownall, HJ; Scott, LW; Sekhar, RV; Smith, EO; Taylor, AA, 2011) |
| "We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 5.14 | Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( D'Emden, M; Ehnholm, C; Fulcher, G; Keech, A; O'Brien, R; Pardy, C; Scott, R; Taskinen, MR; Tse, D, 2009) |
| "To evaluate a new formulation of fenofibric acid (ABT-335) co-administered with 2 doses of rosuvastatin in patients with mixed dyslipidemia." | 5.14 | Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. ( Buttler, SM; Davidson, MH; Jones, PH; Kashyap, ML; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2009) |
| " A total of 657 patients with mixed dyslipidemia (low-density lipoprotein cholesterol [LDL-C] > or =130 mg/dL, triglycerides [TGs] > or =150 mg/dL, and high-density lipoprotein cholesterol [HDL-C]<40 mg/dL [men] or <50 mg/dL [women]) were randomized to 12 weeks of treatment with ABT-335 + simvastatin (20 or 40 mg) combination therapy, ABT-335 monotherapy (135 mg), or simvastatin monotherapy (20, 40, or 80 mg)." | 5.14 | Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. ( Buttler, SM; Kelly, MT; Mohiuddin, SM; Pepine, CJ; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2009) |
| "Fenofibrate is a peroxisome proliferator-activated receptor-alpha (PPARalpha) activator that has been clinically used to treat dyslipidemia and insulin resistance." | 5.14 | Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue. ( Bao, Y; Huang, P; Jia, W; Liu, Y; Lu, J; Wei, L; Wu, H; Xiang, K, 2009) |
| "OBJECTIVE To compare the effect of short-term metformin and fenofibrate treatment, administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors, and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia." | 5.14 | Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. ( Krysiak, R; Okopien, B; Pruski, M, 2009) |
| " We assessed the effects of rimonabant, alone and in combination with fenofibrate or ezetimibe, on adipokine levels in obese/overweight patients with dyslipidemia." | 5.14 | Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study. ( Derdemezis, CS; Elisaf, M; Florentin, M; Liberopoulos, EN; Tellis, CC; Tselepis, A, 2010) |
| "This trial compares the efficacy of administering a combination of ezetimibe plus fenofibrate as an alternative to statin monotherapy for the treatment of dyslipidemia." | 5.14 | Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. ( Day, A; Kumar, SS; LaHaye, SA; Lahey, KA, 2009) |
| "Coadministration of statin and fenofibrate monotherapies is frequently used to treat patients with dyslipidemia; however, a fixed-dose combination (FDC) tablet is not currently marketed." | 5.14 | Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. ( Beckert, M; Davidson, MH; Drucker, J; Eugene Griffin, H; Oosman, S; Rooney, MW, 2009) |
| "We prospectively compared the anti-inflammatory and antidyslipidemic effects of fenofibrate and statins in rheumatoid arthritis (RA) patients." | 5.14 | A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. ( Goto, M, 2010) |
| "To compare fenofibric acid (FA) + statin to respective monotherapies on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia." | 5.14 | The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia. ( Bays, HE; Kelly, MT; McKenney, JM; Obermeyer, K; Roth, EM; Setze, CM; Sleep, DJ; Thakker, KM, 2010) |
| "9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg)." | 5.14 | Effects of medical therapies on retinopathy progression in type 2 diabetes. ( Ambrosius, WT; Chew, EY; Cushman, WC; Danis, RP; Davis, MD; Elam, MB; Esser, BA; Fine, LJ; Gangaputra, S; Genuth, S; Gerstein, HC; Ginsberg, HN; Goff, DC; Greven, CM; Hubbard, L; Lovato, JF; Perdue, LH; Schubart, U, 2010) |
| "Randomized, open-label cross-over study investigating the effect of fenofibrate (160 mg), atorvastatin (10 mg), and combination of both in patients with type 2 diabetes mellitus and atherogenic dyslipidemia." | 5.14 | Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. ( Cariou, B; Costet, P; Guyomarc'h Delasalle, B; Hoffmann, MM; Konrad, T; Winkler, K, 2010) |
| "Statin and ezetimibe combination therapy may be insufficient to improve lipid and nonlipid parameters beyond low-density lipoprotein cholesterol (LDL-C) in patients with mixed dyslipidemia." | 5.14 | Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. ( Goldberg, AC; Jones, PH; Kelly, MT; Knapp, HR; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2010) |
| "In conclusion, rosuvastatin 5 mg + fenofibric acid 135 mg resulted in comprehensive improvements in the lipid profile of patients with mixed dyslipidemia without unanticipated adverse events." | 5.14 | Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. ( Blasetto, JW; Carlson, DM; Fukumoto, SM; Khurmi, NS; Rosenson, RS; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA, 2010) |
| "The combination of rosuvastatin and fenofibric acid (R + FA) results in more comprehensive lipid improvements than corresponding-dose monotherapies, without additional safety concerns, in elderly patients with mixed dyslipidemia." | 5.14 | Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. ( Carlson, DM; Gold, A; Jacobson, TA; Kelly, MT; Pepine, CJ; Setze, CM; Stolzenbach, JC; Williams, LA, 2010) |
| "We assessed the additive effect of dual peroxisome proliferators activated receptors (PPAR) alpha/gamma induction, achieved by the addition of fenofibrate to rosiglitazone, on metabolic control and diabetic dyslipidemia." | 5.12 | The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. ( Altuntas, Y; Basat, O; Seber, S; Ucak, S, 2006) |
| "Patients (n = 300) with type II diabetes, mixed dyslipidemia (2 or more of low-density lipoprotein > or =100 mg/dl, triglycerides > or =200 mg/dl, or high-density lipoprotein <40 mg/dl), and no history of coronary heart disease were randomly assigned to receive simvastatin 20 mg, fenofibrate 160 mg, or a combination of simvastatin 20 mg and fenofibrate 160 mg daily." | 5.12 | The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. ( Anderson, JL; Horne, BD; Jensen, JR; Lanman, RB; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Wolfert, RL; Yannicelli, HD, 2006) |
| "To estimate the effects of 4-weeks therapy of micronized fenofibrate in dose 267 mg/d on C-reactive protein (CRP), fibrinogen, thiobarbituric acid reaction substances (TBARS) concentrations in isolated erythrocyte membranes and the activities of antioxidants enzymes such: catalase (CAT), glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) in erythrocytes in patients with visceral obesity and atherogenic dyslipidemia." | 5.12 | [The anti-inflammatory and antioxidants effects of micronized fenofibrate in patients with visceral obesity and dyslipidemia]. ( Broncel, M; Chojnowska-Jezierska, J; Cieślak, D; Duchnowicz, P; Koter-Michalak, M; Mackiewicz, K, 2006) |
| "Dyslipidemia study: placebo, fenofibrate (200 mg), or LY518674 (10, 25, 50, or 100 microg) for 12 weeks." | 5.12 | Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. ( Gomez, EV; Howey, DC; McErlean, E; Nicholls, SJ; Nissen, SE; Russo, JM; Wang, MD; Wolski, K, 2007) |
| "In 50 patients with Type IIA dyslipidemia were administered rosuvastatin (10 mg daily), whereas in 50 Type IIA dyslipidemic patients exhibiting intolerance to previous statin therapy were administered ezetimibe as monotherapy (10 mg daily)." | 5.12 | Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. ( Elisaf, M; Gazi, IF; Kalogirou, M; Kostapanos, M; Saougos, VG; Tambaki, AP; Tselepis, AD; Wolfert, RL, 2007) |
| "To compare the efficacy of pemafibrate (PF) and fenofibrate (FF) in treating dyslipidemia." | 5.01 | Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate. ( Li, H; Liu, J; Wang, F; Wang, H; Zhao, Q; Zhou, Y, 2019) |
| "Fenofibrate/simvastatin combination is useful for patients with mixed dyslipidemia." | 4.91 | Safety considerations with fenofibrate/simvastatin combination. ( Elisaf, MS; Filippatos, TD, 2015) |
| " Fenofibrate may represent a useful therapeutic option for the treatment of atherogenic dyslipidemia in diabetic subjects." | 4.89 | Summarizing the FIELD study: lessons from a 'negative' trial. ( Elisaf, M; Mikhailidis, DP; Tsimihodimos, V, 2013) |
| "Patients with mixed dyslipidemia can benefit from the combination of fenofibric acid (FA) with statins, but concerns about adverse events make physicians reluctant to prescribe the combination therapy." | 4.89 | Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials. ( Chen, H; Geng, Q; Lee, C; Liang, W; Ren, J, 2013) |
| " Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low- or moderate-dose statin." | 4.88 | A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. ( Filippatos, TD, 2012) |
| "The authors review current literature on the use of fenofibrate and related derivatives in HIV-infected people with dyslipidemia using antiretroviral therapy." | 4.86 | Fenofibrate in the treatment of dyslipidemia associated with HIV infection. ( Fichtenbaum, CJ; Samineni, D, 2010) |
| "Fenofibrate is a PPAR-alpha agonist indicated for the treatment of hypertriglyceridemia and mixed dyslipidemia, and is approved for the treatment of hypercholesterolemia, lipid abnormalities commonly observed in patients at high risk of cardiovascular disease, including Type 2 diabetes and/or metabolic syndromes." | 4.84 | Fenofibrate: treatment of hyperlipidemia and beyond. ( Rosenson, RS, 2008) |
| " Because of concomitant atherogenic dyslipidemia, all patients were treated with fenofibrate (200 mg daily) for 12 weeks." | 3.91 | Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia. ( Krysiak, R; Okopień, B; Szkróbka, W, 2019) |
| "In individual patients with T2DM, there is a wide range of absolute treatment effect of fenofibrate, and overall the fenofibrate treatment effect was larger in patients with dyslipidemia." | 3.88 | Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes. ( Ginsberg, HN; Keech, AC; Koopal, C; van der Graaf, Y; Visseren, FLJ; Westerink, J, 2018) |
| "Purpose - studying of clinical efficiensy of the combined therapy (Amlodipin with Valsartan and fibrates) in hypertensive patients with dyslipidemia." | 3.88 | [THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA]. ( Gegeshidze, N; Kapetivadze, V; Lazashvili, T; Maglapheridze, Z; Tabukashvili, R; Tchaava, K, 2018) |
| "The study included 36 premenopausal women with mixed dyslipidemia and slightly increased prolactin levels, 17 of whom had already been treated with bromocriptine (5." | 3.83 | The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study. ( Krysiak, R; Okopień, B; Okrzesik, J; Szkrobka, W, 2016) |
| "Fenofibrate can ameliorate the dyslipidemia of severely burned rat, and it can alleviate the degree of hepatic steatosis in certain degree." | 3.83 | [Efficacy of fenofibrate for hepatic steatosis in rats after severe burn]. ( Chen, J; Chen, Y; Huang, Z; Meng, C; Yang, C; Zhou, T, 2016) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 3.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| "The study included three age-, weight-, and lipid-matched groups of older men with atherogenic dyslipidemia and late-onset hypogonadism, treated with oral testosterone undecanoate (120 mg daily, n = 15), micronized fenofibrate (200 mg daily, n = 15), or testosterone plus fenofibrate (n = 18)." | 3.81 | The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia. ( Gilowski, W; Krysiak, R; Okopien, B, 2015) |
| "Ursodeoxycholic acid (UDCA) is currently the only available pharmacological treatment for asymptomatic primary biliary cirrhosis (aPBC)." | 3.79 | Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis. ( Dohmen, K; Haruno, M; Tanaka, H, 2013) |
| "05) by treatment with 300 mg fenofibrate once daily for 4 weeks in 13 patients with dyslipidemia." | 3.77 | Activation of peroxisome proliferator-activated receptor α in megakaryocytes reduces platelet-derived growth factor-BB in platelets. ( Abe, M; Aihara, K; Akaike, M; Azuma, H; Hashizume, S; Ikeda, Y; Ishikawa, K; Iwase, T; Matsumoto, T; Sata, M; Sumitomo-Ueda, Y; Yagi, S; Yoshida, S, 2011) |
| "Fenofibrate therapy reduces serum triglycerides (TG) and increases high-density lipoprotein-cholesterol (HDL-C) and thus addresses the atherogenic dyslipidemia associated with metabolic syndrome (MetS)." | 3.77 | Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status. ( An, P; Arnett, DK; Borecki, IB; Feitosa, MF; Hopkins, PN; Ketkar, S; Ordovas, JM; Straka, RJ, 2011) |
| "Fenofibric acid + statin combination therapy in patients with mixed dyslipidemia and type 2 diabetes was well tolerated and resulted in more comprehensive improvement in the lipid/apolipoprotein profile than either monotherapy." | 3.76 | Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. ( Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K, 2010) |
| " Patients were eligible for the analysis if they had a diagnosis of hypertension, dyslipidaemia or diabetes mellitus, were written a prescription for standard fenofibrate 160 mg during the period 1 May 2004 to 30 April 2005, and were written a subsequent prescription for fenofibrate 145 mg NFE at least 60 days after first receiving the 160 mg dose." | 3.74 | Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet. ( Davidson, MH; Jones, PH, 2008) |
| "To compare the effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation with the standard 160-mg tablet in patients with dyslipidemia and coronary heart disease." | 3.74 | Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia. ( Hilleman, D; Maciejewski, S, 2008) |
| "We describe one patient with diabetes mellitus treated by fenofibrate monotherapy since several years; 48 h after gliclazide therapy was introduced, rhabdomyolysis occurred." | 3.73 | [Rhabdomyolysis induced by fenofibrate monotherapy]. ( Amaniou, M; Archambeaud-Mouveroux, F; Combes, C; Galinat, S; Lassandre, S; Lopez, S; Teissier, MP, 2006) |
| " Efficacy of fenofibrate in subjects with moderate risk and type 2 diabetes combined with mild dyslipidemia was studied in the placebo controlled FIELD study." | 3.73 | [Expediency of the use of fibrates for primary and secondary prevention of cardiovascular complications.]. ( Mamedov, MN, 2006) |
| "Patients with type 2 diabetes are at high risk of cardiovascular disease (CVD) in part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol." | 2.84 | Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. ( Buse, JB; Byington, RP; Corson, M; Elam, MB; Fleg, JL; Friedewald, WT; Gerstein, HC; Ginsberg, HN; Goff, DC; Grimm, R; Ismail-Beigi, F; Largay, J; Leiter, LA; Lopez, C; Lovato, LC; O'Connor, PJ; Probstfield, J; Rosenberg, Y; Sweeney, ME; Weiss, D, 2017) |
| "Treatment with fenofibrate significantly improved arterial endothelial function after 4 months." | 2.80 | Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy. ( Celermajer, DS; Harmer, JA; Keech, AC; Marwick, TH; Meredith, IT; Skilton, MR; Veillard, AS; Watts, GF, 2015) |
| "ACCORD enrolled 10,251 type 2 diabetes patients aged 40-79 years at high risk for cardiovascular disease (CVD) events." | 2.79 | Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. ( Buse, JB; Cohen, RM; Cushman, WC; Cutler, JA; Evans, GW; Gerstein, HC; Goff, DC; Grimm, RH; Lipkin, EW; Margolis, KL; Morgan, TM; Narayan, KM; O'Connor, PJ; Riddle, MC; Sood, A, 2014) |
| "To compare the effect of high-dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on the lipoprotein subfraction profile in patients with mixed dyslipidaemia and MetS." | 2.77 | Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. ( Agouridis, AP; Bairaktari, ET; Elisaf, MS; Kostapanos, MS; Kostara, C; Mikhailidis, DP; Tselepis, AD; Tsimihodimos, V, 2012) |
| "Twenty patients with type 2 diabetes and mixed hyperlipidemia were sequentially treated with simvastatin (20 mg/day) and fenofibrate (200 mg/day) in a randomized cross-over study (12 weeks each treatment)." | 2.77 | The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitus. ( Ceska, R; Marinov, I; Skrha, J; Stulc, T, 2012) |
| " In conclusion, these data suggest that a combination of fenofibric acid and a statin could be considered safe and efficacious for treating women with mixed dyslipidemia." | 2.76 | Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia. ( Bittner, V; Goldberg, AC; Kelly, MT; Lele, A; Pepine, CJ; Setze, CM; Sleep, DJ; Thakker, K, 2011) |
| "Atherogenic dyslipidemia is highly associated with coronary heart disease and is characterized by elevated triglycerides (TG), low high-density lipoprotein cholesterol (HDL-C), and elevated low-density lipoprotein cholesterol (LDL-C)." | 2.76 | Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. ( Ballantyne, CM; Belmont, J; Brautbar, A; Covarrubias, D; Jones, PH; Lara-Garduno, F; Leal, SM; Virani, SS, 2011) |
| "The incidence of paradoxical HDL-C reductions was low in mixed dyslipidemic patients receiving FENO alone or combined with EZE or EZE/SIMVA." | 2.76 | Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin. ( Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Shah, A, 2011) |
| " This multicenter, double-blind, active-controlled study evaluated ABT-335 (fenofibric acid) in combination with 2 doses of atorvastatin in patients with mixed dyslipidemia." | 2.74 | Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. ( Ballantyne, CM; Bays, HE; Buttler, SM; Goldberg, AC; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2009) |
| " An unusual dose-response pattern was observed in that at 6 mg/day CP-778,875 only increased HDL cholesterol by 3% and decreased HDL(2) cholesterol by 24%." | 2.73 | Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus. ( Contant, CF; Francone, OL; Gao, X; Lewin, AJ; Nguyen, TT; Terra, SG, 2008) |
| " A comprehensive, controlled clinical trial programme was thus designed to evaluate three separate statins in combination with ABT-335, a new formulation of fenofibric acid." | 2.73 | Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. ( Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2008) |
| "Patients with type 2 diabetes mellitus and no histories of coronary heart disease were evaluated (n = 498)." | 2.73 | Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). ( Anderson, JL; Horne, BD; Jensen, JR; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Yannicelli, HD, 2008) |
| "Fenofibrate treatment led to an increase of the activity of antioxidant enzyme glutathione peroxidase (GPx) by 80% from baseline values (p = 0." | 2.72 | Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity. ( Javorský, M; Kozárová, M; Molcányiová, A; Tkác, I, 2006) |
| "Fenofibrate was associated with less albuminuria progression (p=0." | 2.71 | Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. ( Barter, P; Best, J; Colman, P; d'Emden, M; Davis, T; Drury, P; Ehnholm, C; Forder, P; Glasziou, P; Hunt, D; Keech, A; Kesäniemi, YA; Laakso, M; Pillai, A; Scott, R; Simes, RJ; Sullivan, D; Taskinen, MR; Whiting, M, 2005) |
| "Fenofibrate has also been shown to suppress arrhythmias in isolated rat hearts subjected to ischemic/reperfusion-induced cardiac injury." | 2.61 | Molecular targets of fenofibrate in the cardiovascular-renal axis: A unifying perspective of its pleiotropic benefits. ( Alsayari, A; Balakumar, P; Dhanaraj, SA; Mahadevan, N; Muhsinah, AB; Sambathkumar, R; Venkateswaramurthy, N, 2019) |
| "Dyslipidemia is one of the major cardiovascular risk factors, but beyond statin treatment-which represents the cornerstone of therapy-a relevant practical uncertainty regards the use of fibrate derivatives." | 2.58 | Fenofibrate and Dyslipidemia: Still a Place in Therapy? ( Brunetti, ND; Correale, M; De Gennaro, L; Di Biase, M; Romano, S; Santoro, F; Tarantino, N, 2018) |
| "Statins have a primary role in the treatment of dyslipidemia in people with type 2 diabetes, defined as triglyceride levels >200 mg/dl and HDL cholesterol levels <40 mg/dL." | 2.55 | Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. ( Anabtawi, A; Miles, JM; Moriarty, PM, 2017) |
| "The combination of fenofibrate with statins is a beneficial therapeutic option for patients with mixed dyslipidaemia, but concerns about adverse events (AEs) make physicians reluctant to use this combination therapy." | 2.49 | Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials. ( Chen, H; Geng, Q; Lee, C; Liang, W; Ren, J, 2013) |
| "Diabetic nephropathy is associated with glomerular hypertrophy, glomerulosclerosis, tubulointerstitial fibrosis, mesangial cell expansion, followed by albuminuria and reduction in glomerular filtration rate." | 2.48 | Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney? ( Balakumar, P; Kadian, S; Mahadevan, N, 2012) |
| "Fenofibrate is a third-generation fibric acid derivative employed clinically as a hypolipidemic agent to lessen the risk caused by atherosclerosis." | 2.47 | Pleiotropic actions of fenofibrate on the heart. ( Balakumar, P; Mahadevan, N; Rohilla, A, 2011) |
| "Fenofibrate is a fibric acid derivative with lipid-modifying effects that are mediated by the activation of peroxisome proliferator-activated receptor-α." | 2.47 | Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. ( Keating, GM, 2011) |
| "Fenofibrate is a fibric acid derivative indicated for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia in patients who have not responded to nonpharmacological therapies." | 2.47 | Fenofibrate: a review of its use in dyslipidaemia. ( Keating, GM; McKeage, K, 2011) |
| " The fibrate class of drugs has proven efficacy in improving secondary targets; however, concerns regarding severe myopathy and rhabdomyolysis have limited their combination with statins." | 2.46 | Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid. ( Hilleman, DE; Maciejewski, SR; Mohiuddin, SM; Schima, SM; Williams, MA, 2010) |
| "Low HDL-C levels are common in type 2 diabetes but are not currently recommended as a target for treatment because of the lack of definitive cardiovascular outcome studies supporting this goal, and because of the difficulty in raising HDL-C." | 2.46 | Management of dyslipidemia in people with type 2 diabetes mellitus. ( Dunn, FL, 2010) |
| " It has been extensively evaluated both as monotherapy and in combination with atorvastatin, rosuvastatin, and simvastatin in a large number of patients with mixed dyslipidemia for up to 2 years and appears to be a safe and effective option in the management of dyslipidemia." | 2.46 | Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. ( Elisaf, MS; Kei, A; Milionis, HJ; Moutzouri, E, 2010) |
| "Dyslipidemia is an important modifiable risk factor." | 2.46 | The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes. ( Campbell, J; Mohiuddin, SM, 2010) |
| "Fenofibrate was generally well tolerated alone or in combination with a statin." | 2.45 | More clinical lessons from the FIELD study. ( Fazio, S, 2009) |
| "Microalbuminuria is an early marker of diabetic nephropathy and an independent risk factor for cardiovascular disease." | 2.44 | Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection. ( Brown, WV, 2008) |
| "Mixed dyslipidemia is a common lipid disorder characterized by the presence of an atherogenic lipoprotein phenotype due to abnormalities in various atherogenic and anti-atherogenic lipoproteins." | 2.44 | Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. ( Farnier, M, 2008) |
| "Fenofibrate is a fibric acid derivative indicated for use in the treatment of primary hypercholesterolaemia, mixed dyslipidaemia and hypertriglyceridaemia in adults who have not responded to nonpharmacological measures." | 2.44 | Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. ( Croom, KF; Keating, GM, 2007) |
| "The metabolic syndrome and type 2 diabetes mellitus are both becoming more prevalent, and both increase the risk of cardiovascular disease." | 2.43 | Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. ( Nesto, RW, 2005) |
| " Since fenofibrate was first introduced in clinical practice, a major drawback has been its low bioavailability when taken under fasting conditions." | 2.43 | Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. ( Athyros, VG; Tziomalos, K, 2006) |
| "To assess the cost effectiveness of icosapent ethyl, fenofibrate, ezetimibe, evolocumab, and alirocumab in combination with statins compared to statin monotherapy for cardiovascular prevention from the perspective of UK's National Health Service." | 1.72 | Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy. ( Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T, 2022) |
| "Fenofibrate was associated with a higher incidence of VTE events in diabetic and non-diabetic patients." | 1.51 | Association between venous thromboembolism events and fibrates: A comparative study. ( Alexandre, J; Coquerel, A; Dolladille, C; Faucon, M; Fedrizzi, S; Humbert, X; Lelong-Boulouard, V; Milliez, P; Parienti, JJ; Puddu, PE; Sassier, M; Tournilhac, C, 2019) |
| "Obesity and dyslipidemia is the two facet of metabolic syndrome, which needs further attention." | 1.48 | Novel indole and triazole based hybrid molecules exhibit potent anti-adipogenic and antidyslipidemic activity by activating Wnt3a/β-catenin pathway. ( Babu, MH; Gaikwad, AN; Gupta, A; Kumar, D; Puri, S; Rajan, S; Reddy, MS; Shankar, K; Srivastava, A; Varshney, S, 2018) |
| "Individuals with type 2 diabetes (T2D) and dyslipidemia are at an increased risk of cardiovascular disease." | 1.48 | Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. ( Buse, JB; Doria, A; Gao, H; Ginsberg, HN; Graf, GA; Havener, TM; Jack, JR; Marvel, SW; McLeod, HL; Morieri, ML; Motsinger-Reif, AA; Mychaleckyi, JC; Pijut, SS; Pujol, A; Rotroff, DM; Schluter, A; Shah, HS; Wagner, MJ, 2018) |
| "Fenofibrate was not associated with improved carotid IMT in adults with type 2 diabetes when compared with placebo, despite a statistically significant improvement in TC, LDL-C and TG at 2 and 4 years, and HDL-C at 4 months and 2 years." | 1.48 | Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy. ( Celermajer, DS; Harmer, JA; Keech, AC; Skilton, MR; Veillard, AS; Watts, GF, 2018) |
| " Interactions between statins and other drugs are caused by pharmacokinetic mechanisms, mainly by changing the metabolism of statins in the CYP450 enzyme system, in the hepatic glucuronidation pathway or in the transporters responsible for statin distribution in tissues." | 1.40 | [The combinations of statins and fibrates: pharmacokinetic and clinical implications]. ( González Santos, P, 2014) |
| "Subclinical hypothyroidism is suggested to increase cardiovascular risk." | 1.40 | Different effects of fenofibrate on metabolic and cardiovascular risk factors in mixed dyslipidemic women with normal thyroid function and subclinical hypothyroidism. ( Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W, 2014) |
| "Fenofibrate was associated with a reduction in HDL-C in almost half the patients studied." | 1.35 | Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon. ( Magee, G; Sharpe, PC, 2009) |
| " Once-daily fenofibric acid 135 mg plus a statin was generally as well tolerated as monotherapy with fenofibric acid 135 mg/day or the corresponding statin dosage in the three phase III trials in patients with mixed dyslipidemia." | 1.35 | Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia. ( Keating, GM; Yang, LP, 2009) |
| "Fenofibrate treatment significantly improved lipoprotein metabolism toward a less atherogenic phenotype but did not affect insulin sensitivity." | 1.33 | PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. ( Fiévet, C; Fruchart, JC; Hennuyer, N; Mezdour, H; Staels, B; Tailleux, A; Torpier, G, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 66 (28.82) | 29.6817 |
| 2010's | 150 (65.50) | 24.3611 |
| 2020's | 13 (5.68) | 2.80 |
| Authors | Studies |
|---|---|
| Desai, RC | 1 |
| Metzger, E | 1 |
| Santini, C | 1 |
| Meinke, PT | 2 |
| Heck, JV | 1 |
| Berger, JP | 2 |
| MacNaul, KL | 1 |
| Cai, TQ | 1 |
| Wright, SD | 1 |
| Agrawal, A | 1 |
| Moller, DE | 1 |
| Sahoo, SP | 1 |
| Sierra, ML | 1 |
| Beneton, V | 1 |
| Boullay, AB | 1 |
| Boyer, T | 1 |
| Brewster, AG | 1 |
| Donche, F | 1 |
| Forest, MC | 1 |
| Fouchet, MH | 1 |
| Gellibert, FJ | 1 |
| Grillot, DA | 1 |
| Lambert, MH | 1 |
| Laroze, A | 1 |
| Le Grumelec, C | 1 |
| Linget, JM | 1 |
| Montana, VG | 1 |
| Nguyen, VL | 1 |
| Nicodème, E | 1 |
| Patel, V | 1 |
| Penfornis, A | 1 |
| Pineau, O | 1 |
| Pohin, D | 1 |
| Potvain, F | 1 |
| Poulain, G | 1 |
| Ruault, CB | 1 |
| Saunders, M | 1 |
| Toum, J | 1 |
| Xu, HE | 1 |
| Xu, RX | 1 |
| Pianetti, PM | 1 |
| Liu, W | 1 |
| Liu, K | 1 |
| Wood, HB | 1 |
| McCann, ME | 1 |
| Doebber, TW | 1 |
| Chang, CH | 1 |
| Akiyama, TE | 1 |
| Einstein, M | 1 |
| Shukla, P | 1 |
| Srivastava, SP | 1 |
| Srivastava, R | 2 |
| Rawat, AK | 1 |
| Srivastava, AK | 2 |
| Pratap, R | 2 |
| Rajan, S | 1 |
| Puri, S | 1 |
| Kumar, D | 1 |
| Babu, MH | 1 |
| Shankar, K | 1 |
| Varshney, S | 1 |
| Srivastava, A | 1 |
| Gupta, A | 1 |
| Reddy, MS | 1 |
| Gaikwad, AN | 1 |
| Gupta, J | 1 |
| Singh, DP | 1 |
| Verma, PC | 1 |
| Rahuja, N | 1 |
| Ahmad, I | 1 |
| Jaiswal, N | 1 |
| Kumar, H | 1 |
| Gupta, AP | 1 |
| Gupta, V | 1 |
| Misra, A | 1 |
| Kushwaha, HN | 1 |
| Singh, B | 1 |
| Singh, SK | 1 |
| Dwivedi, AK | 1 |
| Gayen, JR | 1 |
| Sanyal, S | 1 |
| Tamrakar, AK | 1 |
| Sheng, CS | 1 |
| Miao, Y | 1 |
| Ding, L | 1 |
| Cheng, Y | 1 |
| Wang, D | 2 |
| Yang, Y | 1 |
| Tian, J | 1 |
| Honda, A | 1 |
| Kamata, S | 1 |
| Akahane, M | 1 |
| Machida, Y | 1 |
| Uchii, K | 1 |
| Shiiyama, Y | 1 |
| Habu, Y | 1 |
| Miyawaki, S | 1 |
| Kaneko, C | 1 |
| Oyama, T | 1 |
| Ishii, I | 1 |
| Michaeli, DT | 1 |
| Michaeli, JC | 1 |
| Boch, T | 1 |
| Michaeli, T | 1 |
| Khan, MS | 1 |
| Ghumman, GM | 1 |
| Baqi, A | 1 |
| Shah, J | 1 |
| Aziz, M | 1 |
| Mir, T | 1 |
| Tahir, A | 1 |
| Katragadda, S | 1 |
| Singh, H | 1 |
| Taleb, M | 1 |
| Ali, SS | 1 |
| Krysiak, R | 10 |
| Kowalcze, K | 2 |
| Okopień, B | 10 |
| Fruchart, JC | 5 |
| Santos, RD | 1 |
| Wang, H | 1 |
| Li, H | 1 |
| Zhou, Y | 1 |
| Liu, J | 2 |
| Wang, F | 2 |
| Zhao, Q | 1 |
| Blasco, M | 1 |
| Ascaso, JF | 2 |
| Yamashita, S | 3 |
| Masuda, D | 1 |
| Matsuzawa, Y | 1 |
| Zhu, L | 1 |
| Hayen, A | 1 |
| Bell, KJL | 1 |
| Kwon, TG | 1 |
| Jang, AY | 1 |
| Kim, SW | 1 |
| Hong, YJ | 2 |
| Bae, JH | 1 |
| Lee, SY | 1 |
| Kim, SH | 1 |
| Han, SH | 1 |
| Ihm, SH | 1 |
| Chung, WB | 1 |
| Lee, JM | 1 |
| Hwang, BH | 1 |
| Yoo, KD | 1 |
| Her, SH | 1 |
| Song, WH | 1 |
| Chae, IH | 1 |
| Park, TH | 1 |
| Kim, JH | 1 |
| Jeon, DW | 1 |
| Cho, BR | 1 |
| Kang, SH | 1 |
| Park, SD | 1 |
| Lee, JB | 1 |
| Woo, JT | 1 |
| Lee, BW | 1 |
| Han, KA | 1 |
| Won, KH | 1 |
| Kim, HS | 1 |
| Yu, JM | 1 |
| Chung, CH | 1 |
| Kim, HJ | 1 |
| Cho, HC | 1 |
| Seung, KB | 1 |
| Lizunov, AV | 1 |
| Okunevich, IV | 1 |
| Lebedev, AA | 1 |
| Bychkov, ER | 1 |
| Piotrovskiy, LB | 1 |
| Shabanov, PD | 1 |
| Shin, Y | 1 |
| Lee, M | 1 |
| Lee, D | 1 |
| Jang, J | 1 |
| Shin, SS | 1 |
| Yoon, M | 1 |
| Anabtawi, A | 1 |
| Moriarty, PM | 1 |
| Miles, JM | 1 |
| Rotroff, DM | 1 |
| Pijut, SS | 1 |
| Marvel, SW | 1 |
| Jack, JR | 1 |
| Havener, TM | 1 |
| Pujol, A | 1 |
| Schluter, A | 1 |
| Graf, GA | 1 |
| Ginsberg, HN | 7 |
| Shah, HS | 1 |
| Gao, H | 1 |
| Morieri, ML | 1 |
| Doria, A | 1 |
| Mychaleckyi, JC | 1 |
| McLeod, HL | 1 |
| Buse, JB | 3 |
| Wagner, MJ | 1 |
| Motsinger-Reif, AA | 1 |
| Shi, T | 1 |
| Lu, K | 1 |
| Shen, S | 1 |
| Tang, Q | 1 |
| Zhang, K | 1 |
| Zhu, X | 1 |
| Shi, Y | 1 |
| Liu, X | 2 |
| Teng, H | 1 |
| Li, C | 1 |
| Xue, B | 1 |
| Jiang, Q | 1 |
| Koopal, C | 1 |
| Visseren, FLJ | 1 |
| Westerink, J | 1 |
| van der Graaf, Y | 1 |
| Keech, AC | 4 |
| Harmer, JA | 2 |
| Veillard, AS | 2 |
| Skilton, MR | 2 |
| Watts, GF | 8 |
| Celermajer, DS | 2 |
| Streja, E | 1 |
| Streja, DA | 1 |
| Soohoo, M | 1 |
| Kleine, CE | 1 |
| Hsiung, JT | 1 |
| Park, C | 1 |
| Moradi, H | 1 |
| Tarantino, N | 2 |
| Santoro, F | 2 |
| Correale, M | 2 |
| De Gennaro, L | 2 |
| Romano, S | 1 |
| Di Biase, M | 2 |
| Brunetti, ND | 2 |
| Han, JS | 1 |
| Kim, K | 1 |
| Jung, Y | 1 |
| Lee, JH | 1 |
| Namgung, J | 1 |
| Lee, HY | 1 |
| Suh, J | 1 |
| Hwang, GS | 1 |
| Lee, SH | 1 |
| Wang, HY | 1 |
| Jiao, QP | 1 |
| Chen, SY | 1 |
| Sheng, J | 1 |
| Jiang, H | 1 |
| Lu, J | 2 |
| Zheng, SB | 1 |
| Fang, NY | 1 |
| Tabukashvili, R | 1 |
| Kapetivadze, V | 1 |
| Tchaava, K | 1 |
| Gegeshidze, N | 1 |
| Lazashvili, T | 1 |
| Maglapheridze, Z | 1 |
| Szkróbka, W | 3 |
| Dolladille, C | 1 |
| Humbert, X | 1 |
| Faucon, M | 1 |
| Tournilhac, C | 1 |
| Sassier, M | 1 |
| Fedrizzi, S | 1 |
| Milliez, P | 1 |
| Lelong-Boulouard, V | 1 |
| Coquerel, A | 1 |
| Puddu, PE | 1 |
| Parienti, JJ | 1 |
| Alexandre, J | 1 |
| Balakumar, P | 3 |
| Sambathkumar, R | 1 |
| Mahadevan, N | 3 |
| Muhsinah, AB | 1 |
| Alsayari, A | 1 |
| Venkateswaramurthy, N | 1 |
| Dhanaraj, SA | 1 |
| Kei, A | 5 |
| Liberopoulos, EN | 4 |
| Mikhailidis, DP | 7 |
| Elisaf, M | 9 |
| Susecov, AV | 1 |
| Al-Waili, K | 1 |
| Al-Zakwani, I | 1 |
| Al-Dughaishi, T | 1 |
| Baneerje, Y | 1 |
| Al-Sabti, H | 1 |
| Al-Hashmi, K | 1 |
| Farhan, H | 1 |
| Habsi, KA | 1 |
| Al-Hinai, AT | 1 |
| Al-Rasadi, K | 1 |
| Liberopoulos, E | 3 |
| Tellis, K | 1 |
| Rizzo, M | 2 |
| Tselepis, A | 4 |
| Brautbar, A | 5 |
| Barbalic, M | 1 |
| Chen, F | 1 |
| Belmont, J | 3 |
| Virani, SS | 4 |
| Scherer, S | 1 |
| Hegele, RA | 1 |
| Ballantyne, CM | 8 |
| Weinstein, DL | 1 |
| Williams, LA | 5 |
| Carlson, DM | 6 |
| Kelly, MT | 15 |
| Burns, KM | 1 |
| Setze, CM | 15 |
| Lele, A | 5 |
| Stolzenbach, JC | 12 |
| Chen, M | 1 |
| Deng, D | 1 |
| Fang, Z | 1 |
| Xu, M | 1 |
| Hu, H | 1 |
| Luo, L | 1 |
| Wang, Y | 1 |
| Tellis, C | 2 |
| Sahebkar, A | 2 |
| Niesor, EJ | 1 |
| Gauthamadasa, K | 1 |
| Silva, RA | 1 |
| Suchankova, G | 1 |
| Kallend, D | 1 |
| Gylling, H | 1 |
| Asztalos, B | 1 |
| Damonte, E | 1 |
| Rossomanno, S | 1 |
| Abt, M | 1 |
| Davidson, WS | 1 |
| Benghozi, R | 1 |
| Tsimihodimos, V | 4 |
| Kitajima, S | 1 |
| Furuichi, K | 1 |
| Wada, T | 1 |
| Linz, PE | 1 |
| Lovato, LC | 2 |
| Byington, RP | 2 |
| O'Connor, PJ | 3 |
| Leiter, LA | 2 |
| Weiss, D | 2 |
| Force, RW | 1 |
| Crouse, JR | 1 |
| Ismail-Beigi, F | 2 |
| Simmons, DL | 1 |
| Papademetriou, V | 1 |
| Elam, MB | 3 |
| Chew, GT | 3 |
| Dohmen, K | 1 |
| Tanaka, H | 1 |
| Haruno, M | 1 |
| Harivenkatesh, N | 1 |
| David, DC | 1 |
| Haribalaji, N | 1 |
| Sudhakar, MK | 1 |
| Margolis, KL | 1 |
| Morgan, TM | 1 |
| Cohen, RM | 1 |
| Cushman, WC | 2 |
| Cutler, JA | 1 |
| Evans, GW | 1 |
| Gerstein, HC | 3 |
| Grimm, RH | 1 |
| Lipkin, EW | 1 |
| Narayan, KM | 1 |
| Riddle, MC | 1 |
| Sood, A | 1 |
| Goff, DC | 3 |
| Gao, F | 1 |
| Ballantyne, C | 1 |
| Ma, L | 2 |
| Keinan, A | 2 |
| Sharma, A | 1 |
| Joshi, PH | 1 |
| Rinehart, S | 1 |
| Thakker, KM | 3 |
| Voros, S | 1 |
| Davidson, MH | 9 |
| Rosenson, RS | 7 |
| Maki, KC | 3 |
| Nicholls, SJ | 3 |
| Mazzone, T | 1 |
| Camp, HS | 1 |
| Hong, YA | 1 |
| Lim, JH | 1 |
| Kim, MY | 1 |
| Kim, TW | 1 |
| Kim, Y | 1 |
| Yang, KS | 1 |
| Park, HS | 1 |
| Choi, SR | 1 |
| Chung, S | 1 |
| Kim, HW | 2 |
| Choi, BS | 1 |
| Chang, YS | 1 |
| Park, CW | 1 |
| González Santos, P | 1 |
| Díaz Rodríguez, Á | 1 |
| Pedro-Botet, J | 1 |
| Flores-Le Roux, JA | 1 |
| Mantilla, T | 1 |
| Núñez-Cortés, JM | 1 |
| Pintó, X | 1 |
| Grandi, AM | 1 |
| Nicolini, E | 1 |
| Rizzi, L | 1 |
| Caputo, S | 1 |
| Annoni, F | 1 |
| Cremona, AM | 1 |
| Marchesi, C | 1 |
| Guasti, L | 1 |
| Maresca, AM | 1 |
| Grossi, P | 1 |
| González, DF | 1 |
| Gilowski, W | 2 |
| Khera, AV | 1 |
| Qamar, A | 1 |
| Reilly, MP | 1 |
| Dunbar, RL | 1 |
| Rader, DJ | 1 |
| Masana, L | 1 |
| Cabré, A | 1 |
| Heras, M | 1 |
| Amigó, N | 1 |
| Correig, X | 1 |
| Martínez-Hervás, S | 1 |
| Real, JT | 1 |
| Quesada, H | 1 |
| Julve, J | 1 |
| Palomer, X | 1 |
| Vázquez-Carrera, M | 1 |
| Girona, J | 1 |
| Plana, N | 1 |
| Blanco-Vaca, F | 1 |
| Kalina, MA | 1 |
| Wilczek, M | 1 |
| Kalina-Faska, B | 1 |
| Skała-Zamorowska, E | 1 |
| Mandera, M | 1 |
| Małecka Tendera, E | 1 |
| Dubé, MP | 1 |
| Komarow, L | 1 |
| Fichtenbaum, CJ | 2 |
| Cadden, JJ | 1 |
| Overton, ET | 1 |
| Hodis, HN | 1 |
| Currier, JS | 1 |
| Stein, JH | 1 |
| Filippatos, TD | 5 |
| Elisaf, MS | 7 |
| Gdula-Dymek, A | 2 |
| Marek, B | 2 |
| Foucher, C | 2 |
| Aubonnet, P | 1 |
| Reichert, P | 1 |
| Berli, M | 1 |
| Schaeffer, A | 1 |
| Calvo Vargas, CG | 1 |
| Lochocka, A | 1 |
| Belenky, D | 1 |
| Koch, HF | 1 |
| Marwick, TH | 1 |
| Meredith, IT | 1 |
| Aguiar, C | 1 |
| Alegria, E | 1 |
| Bonadonna, RC | 1 |
| Catapano, AL | 1 |
| Cosentino, F | 1 |
| Farnier, M | 3 |
| Ferrières, J | 1 |
| Filardi, PP | 1 |
| Hancu, N | 1 |
| Kayikcioglu, M | 1 |
| Mello E Silva, A | 1 |
| Millan, J | 1 |
| Reiner, Ž | 1 |
| Tokgozoglu, L | 1 |
| Valensi, P | 1 |
| Viigimaa, M | 1 |
| Vrablik, M | 1 |
| Zambon, A | 2 |
| Zamorano, JL | 1 |
| Ferrari, R | 1 |
| Rosolová, H | 2 |
| Okrzesik, J | 1 |
| Tsunoda, F | 1 |
| Asztalos, IB | 1 |
| Horvath, KV | 1 |
| Steiner, G | 2 |
| Schaefer, EJ | 1 |
| Asztalos, BF | 1 |
| Ishibashi, S | 1 |
| Arai, H | 1 |
| Araki, E | 1 |
| Yokote, K | 1 |
| Suganami, H | 1 |
| Kodama, T | 1 |
| Márk, L | 1 |
| Dani, G | 1 |
| Huang, Z | 1 |
| Meng, C | 1 |
| Chen, J | 1 |
| Chen, Y | 2 |
| Zhou, T | 1 |
| Yang, C | 1 |
| Sampietro, T | 1 |
| Sbrana, F | 1 |
| Bigazzi, F | 1 |
| Dal Pino, B | 1 |
| Luciani, R | 1 |
| Pianelli, M | 1 |
| Marconcini, C | 1 |
| Pisciotta, L | 1 |
| Zhao, S | 1 |
| Dai, Y | 1 |
| Lin, L | 1 |
| Tong, Q | 1 |
| Liao, Y | 1 |
| Yin, Y | 1 |
| Wang, G | 1 |
| Yan, Y | 1 |
| Li, X | 1 |
| Wei, P | 1 |
| Cheng, X | 1 |
| Xie, Q | 1 |
| Sun, Y | 1 |
| Fu, G | 1 |
| Huang, H | 1 |
| Dong, Y | 1 |
| Yan, J | 1 |
| Yan, L | 1 |
| Cui, S | 1 |
| Li, Z | 1 |
| Chen, H | 3 |
| Hu, T | 1 |
| Gong, H | 1 |
| Knickelbein, JE | 1 |
| Abbott, AB | 1 |
| Chew, EY | 2 |
| Corson, M | 1 |
| Largay, J | 1 |
| Lopez, C | 1 |
| Sweeney, ME | 1 |
| Friedewald, WT | 1 |
| Probstfield, J | 1 |
| Grimm, R | 1 |
| Fleg, JL | 1 |
| Rosenberg, Y | 1 |
| Guastafierro, F | 1 |
| Gaglione, A | 1 |
| Chan, DC | 3 |
| Ooi, EM | 1 |
| Ji, J | 1 |
| Johnson, AG | 1 |
| Barrett, PH | 1 |
| Abbasi, F | 1 |
| Chen, YD | 1 |
| Farin, HM | 1 |
| Lamendola, C | 1 |
| Reaven, GM | 1 |
| Mansouri, RM | 1 |
| Baugé, E | 1 |
| Gervois, P | 1 |
| Fruchart-Najib, J | 1 |
| Fiévet, C | 2 |
| Staels, B | 3 |
| Terra, SG | 1 |
| Francone, OL | 1 |
| Contant, CF | 1 |
| Gao, X | 1 |
| Lewin, AJ | 1 |
| Nguyen, TT | 1 |
| Jones, PH | 7 |
| Bays, HE | 5 |
| Buttler, SM | 4 |
| Sleep, DJ | 9 |
| Ramakrishnan, R | 1 |
| Scott, R | 2 |
| O'Brien, R | 1 |
| Fulcher, G | 1 |
| Pardy, C | 1 |
| D'Emden, M | 2 |
| Tse, D | 1 |
| Taskinen, MR | 4 |
| Ehnholm, C | 3 |
| Keech, A | 2 |
| Kashyap, ML | 1 |
| Mohiuddin, SM | 4 |
| Pepine, CJ | 3 |
| Brown, WV | 1 |
| Wu, H | 1 |
| Wei, L | 1 |
| Bao, Y | 1 |
| Huang, P | 1 |
| Liu, Y | 1 |
| Jia, W | 1 |
| Xiang, K | 1 |
| Fazio, S | 1 |
| Dodson, PM | 2 |
| Goldberg, AC | 3 |
| Magee, G | 1 |
| Sharpe, PC | 1 |
| Sullivan, DR | 1 |
| Whiting, M | 2 |
| Zannino, D | 1 |
| Simes, RJ | 2 |
| Barter, PJ | 1 |
| Pruski, M | 1 |
| Derosa, G | 1 |
| Maffioli, P | 1 |
| Salvadeo, SA | 1 |
| Ferrari, I | 1 |
| Gravina, A | 1 |
| Mereu, R | 1 |
| Palumbo, I | 1 |
| D'Angelo, A | 1 |
| Cicero, AF | 1 |
| Unnikrishnan, R | 1 |
| Das, R | 1 |
| Jaydip, R | 1 |
| Sudhakaran, C | 1 |
| Mohan, V | 1 |
| Simó, R | 1 |
| Hernández, C | 1 |
| Troutt, JS | 1 |
| Alborn, WE | 1 |
| Cao, G | 1 |
| Konrad, RJ | 1 |
| Florentin, M | 1 |
| Tellis, CC | 2 |
| Derdemezis, CS | 1 |
| Yang, LP | 1 |
| Keating, GM | 4 |
| Kipnes, MS | 1 |
| Roth, EM | 3 |
| Rhyne, JM | 1 |
| Kumar, SS | 1 |
| Lahey, KA | 1 |
| Day, A | 1 |
| LaHaye, SA | 1 |
| Rooney, MW | 1 |
| Drucker, J | 1 |
| Eugene Griffin, H | 1 |
| Oosman, S | 1 |
| Beckert, M | 1 |
| Cusi, K | 2 |
| Thakker, K | 2 |
| Goto, M | 1 |
| Im, M | 1 |
| Kim, M | 1 |
| Lee, JK | 1 |
| Chang, YH | 1 |
| Lee, DY | 1 |
| Hong, SI | 1 |
| Lee, YY | 1 |
| Schima, SM | 1 |
| Maciejewski, SR | 1 |
| Hilleman, DE | 1 |
| Williams, MA | 1 |
| Dunn, FL | 1 |
| Mombelli, G | 1 |
| Pazzucconi, F | 1 |
| Bondioli, A | 1 |
| Zanaboni, A | 1 |
| Gaito, S | 1 |
| Calabresi, L | 1 |
| Sirtori, CR | 1 |
| Brugère, L | 1 |
| Ansquer, JC | 1 |
| Alagona, P | 1 |
| Tenenbaum, A | 2 |
| Fisman, EZ | 2 |
| McKenney, JM | 1 |
| Obermeyer, K | 1 |
| Ambrosius, WT | 1 |
| Davis, MD | 1 |
| Danis, RP | 1 |
| Gangaputra, S | 1 |
| Greven, CM | 1 |
| Hubbard, L | 1 |
| Esser, BA | 1 |
| Lovato, JF | 1 |
| Perdue, LH | 1 |
| Genuth, S | 1 |
| Schubart, U | 1 |
| Fine, LJ | 1 |
| Samineni, D | 1 |
| Ruiz, J | 1 |
| Egli, M | 1 |
| Gianinazzi, F | 1 |
| Izzo, F | 1 |
| Voeffray Favre, AC | 1 |
| Rossi, I | 1 |
| Bodenman, P | 1 |
| Costet, P | 1 |
| Hoffmann, MM | 1 |
| Cariou, B | 1 |
| Guyomarc'h Delasalle, B | 1 |
| Konrad, T | 1 |
| Winkler, K | 1 |
| Laakso, M | 2 |
| Hamilton, SJ | 1 |
| Rye, KA | 1 |
| Jenkins, AJ | 1 |
| Lambert, G | 1 |
| Michie, CO | 1 |
| Sakala, M | 1 |
| Rivans, I | 1 |
| Strachan, MW | 1 |
| Clive, S | 1 |
| Pérez, A | 1 |
| Moutzouri, E | 1 |
| Milionis, HJ | 1 |
| Sacks, FM | 1 |
| Carey, VJ | 1 |
| Kucera, M | 1 |
| Oravec, S | 1 |
| Ocadlík, I | 1 |
| Knapp, HR | 1 |
| Fukumoto, SM | 1 |
| Blasetto, JW | 1 |
| Khurmi, NS | 1 |
| Jacobson, TA | 1 |
| Gold, A | 1 |
| Hashizume, S | 1 |
| Akaike, M | 1 |
| Azuma, H | 1 |
| Ishikawa, K | 1 |
| Yoshida, S | 1 |
| Sumitomo-Ueda, Y | 1 |
| Yagi, S | 1 |
| Ikeda, Y | 1 |
| Iwase, T | 1 |
| Aihara, K | 1 |
| Abe, M | 1 |
| Sata, M | 1 |
| Matsumoto, T | 1 |
| Campbell, J | 1 |
| Rohilla, A | 1 |
| Enger, C | 1 |
| Gately, R | 1 |
| Ming, EE | 1 |
| Niemcryk, SJ | 1 |
| Williams, L | 1 |
| McAfee, AT | 1 |
| Baum, SJ | 1 |
| Shah, A | 2 |
| Macdonell, G | 1 |
| Taggart, WV | 1 |
| Gumbiner, B | 1 |
| Hirshberg, B | 1 |
| Paraskevas, KI | 1 |
| Pantopoulou, A | 1 |
| Vlachos, IS | 1 |
| Agrogiannis, G | 1 |
| Iliopoulos, DG | 1 |
| Karatzas, G | 1 |
| Tzivras, D | 1 |
| Perrea, DN | 1 |
| Bittner, V | 1 |
| Feitosa, MF | 1 |
| An, P | 1 |
| Ordovas, JM | 2 |
| Ketkar, S | 1 |
| Hopkins, PN | 1 |
| Straka, RJ | 1 |
| Arnett, DK | 2 |
| Borecki, IB | 1 |
| Agouridis, AP | 4 |
| Tselepis, AD | 4 |
| Balasubramanyam, A | 1 |
| Coraza, I | 1 |
| Smith, EO | 1 |
| Scott, LW | 1 |
| Patel, P | 1 |
| Iyer, D | 1 |
| Taylor, AA | 1 |
| Giordano, TP | 1 |
| Sekhar, RV | 1 |
| Clark, P | 1 |
| Cuevas-Sanchez, E | 1 |
| Kamble, S | 1 |
| Pownall, HJ | 1 |
| Grinspoon, S | 1 |
| Fitch, K | 1 |
| Dimitriou, AA | 1 |
| Lim, LS | 1 |
| Wong, TY | 1 |
| Liu, Q | 2 |
| Liu, SN | 2 |
| Li, LY | 2 |
| Chen, ZY | 1 |
| Lei, L | 1 |
| Zhang, N | 1 |
| Shen, ZF | 2 |
| Goldfine, AB | 1 |
| Kaul, S | 1 |
| Hiatt, WR | 1 |
| Liamina, NP | 1 |
| Karpova, ÉS | 1 |
| Kotel'nikova, EV | 1 |
| Nosenko, AN | 1 |
| Covarrubias, D | 1 |
| Lara-Garduno, F | 1 |
| Leal, SM | 1 |
| Amend, KL | 1 |
| Landon, J | 1 |
| Thyagarajan, V | 1 |
| Niemcryk, S | 1 |
| McAfee, A | 1 |
| McKeage, K | 1 |
| Susekov, AV | 1 |
| Khokhlova, NV | 1 |
| Huan, Y | 1 |
| Sun, SJ | 1 |
| Dong, Q | 1 |
| Johnson-Levonas, AO | 1 |
| Brudi, P | 1 |
| Łabuzek, K | 1 |
| Bułdak, Ł | 1 |
| Duława-Bułdak, A | 1 |
| Bielecka, A | 1 |
| Madej, A | 1 |
| Schäfer, HL | 1 |
| Linz, W | 1 |
| Falk, E | 1 |
| Glien, M | 1 |
| Glombik, H | 1 |
| Korn, M | 1 |
| Wendler, W | 1 |
| Herling, AW | 1 |
| Rütten, H | 1 |
| Rosenblit, PD | 1 |
| Nambi, V | 1 |
| Ferdinand, KC | 1 |
| Kadian, S | 1 |
| Bandgar, TR | 1 |
| Faruqui, AA | 1 |
| Wong, AT | 1 |
| Lewis, D | 1 |
| Wanner, C | 1 |
| Makariou, SE | 1 |
| Challa, A | 1 |
| Davidson, M | 1 |
| Setze, C | 1 |
| Stolzenbach, J | 1 |
| van Bochove, K | 1 |
| van Schalkwijk, DB | 1 |
| Parnell, LD | 1 |
| Lai, CQ | 1 |
| de Graaf, AA | 1 |
| van Ommen, B | 1 |
| Pecora, V | 1 |
| Nucera, E | 1 |
| Aruanno, A | 1 |
| Buonomo, A | 1 |
| Schiavino, D | 1 |
| Belmont, JW | 1 |
| Kostapanos, MS | 1 |
| Kostara, C | 1 |
| Bairaktari, ET | 1 |
| Lee, CY | 1 |
| Huang, KH | 1 |
| Lin, CC | 1 |
| Tsai, TH | 1 |
| Shih, HC | 1 |
| Stulc, T | 1 |
| Ceska, R | 2 |
| Marinov, I | 1 |
| Skrha, J | 1 |
| Geng, Q | 2 |
| Ren, J | 2 |
| Lee, C | 2 |
| Liang, W | 2 |
| Glineur, C | 1 |
| Gross, B | 1 |
| Neve, B | 1 |
| Rommens, C | 1 |
| Martin-Nizard, F | 1 |
| Rodríguez-Pascual, F | 1 |
| Lamas, S | 1 |
| Hennuyer, N | 1 |
| Tailleux, A | 1 |
| Torpier, G | 1 |
| Mezdour, H | 1 |
| Seber, S | 1 |
| Ucak, S | 1 |
| Basat, O | 1 |
| Altuntas, Y | 1 |
| Nesto, RW | 1 |
| Chironi, G | 1 |
| Simon, A | 1 |
| Gariepy, J | 1 |
| Balice, M | 1 |
| Del-Pino, M | 1 |
| Levenson, J | 1 |
| Barter, P | 1 |
| Best, J | 1 |
| Forder, P | 1 |
| Pillai, A | 1 |
| Davis, T | 1 |
| Glasziou, P | 1 |
| Drury, P | 1 |
| Kesäniemi, YA | 1 |
| Sullivan, D | 1 |
| Hunt, D | 1 |
| Colman, P | 1 |
| Tkác, I | 1 |
| Molcányiová, A | 1 |
| Javorský, M | 1 |
| Kozárová, M | 1 |
| Radermecker, RP | 1 |
| Scheen, AJ | 1 |
| Athyros, VG | 3 |
| Didangelos, TP | 1 |
| Giouleme, OI | 1 |
| Karagiannis, A | 2 |
| Kakafika, AI | 2 |
| Tziomalos, K | 2 |
| Burroughs, AK | 1 |
| Archambeaud-Mouveroux, F | 1 |
| Lopez, S | 1 |
| Combes, C | 1 |
| Lassandre, S | 1 |
| Amaniou, M | 1 |
| Teissier, MP | 1 |
| Galinat, S | 1 |
| Serisier, S | 1 |
| Briand, F | 1 |
| Ouguerram, K | 1 |
| Siliart, B | 1 |
| Magot, T | 1 |
| Nguyen, P | 1 |
| Stein, E | 1 |
| Shalwitz, RA | 1 |
| Doyle, R | 1 |
| Rees, A | 1 |
| Muhlestein, JB | 2 |
| May, HT | 2 |
| Jensen, JR | 2 |
| Horne, BD | 2 |
| Lanman, RB | 1 |
| Lavasani, F | 2 |
| Wolfert, RL | 2 |
| Pearson, RR | 2 |
| Yannicelli, HD | 2 |
| Anderson, JL | 2 |
| Broncel, M | 1 |
| Cieślak, D | 1 |
| Koter-Michalak, M | 1 |
| Duchnowicz, P | 1 |
| Mackiewicz, K | 1 |
| Chojnowska-Jezierska, J | 1 |
| Croom, KF | 1 |
| Aronow, WS | 1 |
| Mamedov, MN | 1 |
| Nissen, SE | 1 |
| Wolski, K | 1 |
| Howey, DC | 1 |
| McErlean, E | 1 |
| Wang, MD | 1 |
| Gomez, EV | 1 |
| Russo, JM | 1 |
| Berneis, K | 1 |
| Bláha, V | 1 |
| Hamouz, Z | 1 |
| Pelikánová, T | 1 |
| Soska, V | 1 |
| Soucek, M | 1 |
| Sucharda, P | 1 |
| Saougos, VG | 1 |
| Tambaki, AP | 1 |
| Kalogirou, M | 1 |
| Kostapanos, M | 1 |
| Gazi, IF | 1 |
| Benatar, JR | 1 |
| Stewart, RA | 1 |
| Plutzky, J | 1 |
| Chrysohoou, C | 1 |
| Singh, S | 1 |
| Cannon, CP | 1 |
| Maciejewski, S | 1 |
| Hilleman, D | 1 |
| Koragiannis, A | 1 |
| Mikhalidis, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Action to Control Cardiovascular Risk in Diabetes (ACCORD)[NCT00000620] | Phase 3 | 10,251 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| The Comparative Analysis of the Effects on Plaque Volume and Tissue Characteristics Between Combined Therapy With STAatin Plus FENOfibrate and Statin Alone in Mild to Moderate, Non- Intervened Coronary Artery Stenosis (STAFENO Trial)[NCT02232360] | Phase 4 | 106 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin Versus Pitavastatin/Fenofibrate in Complex-dyslipidemia Patients[NCT03618797] | Phase 3 | 347 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia[NCT01010516] | Phase 4 | 120 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | ||
| A 30-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects With Stage 3 Chronic Kidney Disease[NCT00680017] | Phase 3 | 280 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Confirmatory Study of the Efficacy and Safety of the Fixed-dose Combination Atorvastatin / Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients With Type 2 Diabetes (T2D) and Dyslipidaemia (DLP).[NCT04882293] | Phase 3 | 78 participants (Anticipated) | Interventional | 2022-02-15 | Recruiting | ||
| Effect of HDL-Raising Therapies on Endothelial Function, Lipoproteins, and Inflammation in HIV-infected Subjects With Low HDL Cholesterol: A Phase II Randomized Trial of Extended Release Niacin vs. Fenofibrate[NCT01426438] | Phase 2 | 99 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study[NCT00542178] | Phase 3 | 3,472 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Atorvastatin Calcium Combination Therapy to Fenofibric Acid and Atorvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia[NCT00300469] | Phase 3 | 613 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Rosuvastatin Calcium Combination Therapy to Fenofibric Acid and Rosuvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia[NCT00300482] | Phase 3 | 1,445 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of ABT-335 and Simvastatin Combination Therapy to ABT-335 and Simvastatin Monotherapy in Subjects With Mixed Dyslipidemia[NCT00300456] | Phase 3 | 657 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Long-Term, Open-Label, Safety Extension Study of the Combination of Fenofibric Acid and Statin Therapy for Subjects With Mixed Dyslipidemia[NCT00300430] | Phase 3 | 1,911 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Comparison of the Efficacy and AtorVastatin 20mg mOnotherapy Versus Combination Atorvastatin/Fenofibric Acid 10/135mg in the Mixed hyperlipiDemia Who Were Not at Lipid gOals With Atorvastatin 10mg Monotherapy.[NCT01974297] | 194 participants (Anticipated) | Interventional | 2013-07-31 | Recruiting | |||
| A Year 2, Long-Term, Open-Label, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia[NCT00491530] | Phase 3 | 310 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A 12-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group Study, Followed by a 12 Month Extension Study, of the Efficacy and Safety of LCP-AtorFen in Subjects With Dyslipidemia[NCT00504829] | Phase 2 | 220 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of ABT-335 in Combination With Atorvastatin and Ezetimibe to Atorvastatin in Combination With Ezetimibe in Subjects With Combined (Atherogenic) Dyslipidemia[NCT00639158] | Phase 3 | 543 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A 12-week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to ABT-335 and Rosuvastatin Monotherapy in Subjects With Type IIa and IIb Dyslipidemia[NCT00463606] | Phase 3 | 760 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy[NCT00246376] | 221 participants (Actual) | Interventional | 2004-01-31 | Completed | |||
| Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia[NCT00092573] | Phase 3 | 576 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia[NCT00092560] | Phase 3 | 587 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects With Type IIb Dyslipidemia With Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial[NCT00616772] | Phase 3 | 682 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy[NCT03869931] | Phase 3 | 300 participants (Anticipated) | Interventional | 2019-03-08 | Recruiting | ||
| A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)[NCT01152073] | 79 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study: A Randomized, Double-Blind Study of Simvastatin, Fenofibrate, and Combined Fenofibrate and Simvastatin in Patients With Controlled Type II Diabetics Without Evidence of Coronary Disease[NCT00309712] | 300 participants | Interventional | 2002-08-31 | Completed | |||
| PPAR Alpha (LY518674): A Phase 2 Study of the Combinatorial Effect of LY518674 and Atorvastatin in Subjects With Hypercholesterolemia[NCT00133380] | Phase 2 | 300 participants | Interventional | 2005-07-31 | Completed | ||
| PPAR Alpha: A Phase 2 Dose-Finding and Safety Study for Atherogenic Dyslipidemia by Eli Lilly[NCT00116519] | Phase 2 | 300 participants | Interventional | 2005-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 391 |
| Glycemia Trial: Standard Control | 327 |
"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 503 |
| Glycemia Trial: Standard Control | 543 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 208 |
| BP Trial: Standard Control | 237 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 291 |
| Lipid Trial: Placebo | 310 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 641 |
| Lipid Trial: Placebo | 667 |
Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 36 |
| BP Trial: Standard Control | 62 |
High-density lipoprotein cholesterol (HDL-C) was measured in milligrams/deciliter (mg/dL). (NCT00680017)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| ABT-335 Plus Rosuvastatin | 16.9 |
| Rosuvastatin | 7.8 |
Triglycerides were measured in milligrams/deciliter. (NCT00680017)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Median) |
|---|---|
| ABT-335 Plus Rosuvastatin | -38.0 |
| Rosuvastatin | -22.4 |
The absolute change in maximum relative flow mediated dilation (FMD) (%) of the brachial artery from baseline to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | % FMD (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 0.60 |
| Arm B: Fenofibrate | 0.50 |
Change in C-reactive protein from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | ug/ml (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -0.6 |
| Arm B: Fenofibrate | 0.7 |
Absolute change in total cholesterol from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -9 |
| Arm B: Fenofibrate | -2 |
Change in D-Dimer from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | ug/ml (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 0.06 |
| Arm B: Fenofibrate | 0.06 |
Change in total HDL particles from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | nmol/L (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -1.7 |
| Arm B: Fenofibrate | 4.3 |
Absolute change from week 0 to week 24 in insulin resistance as estimated by HOMA-IR (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | HOMA IR Score (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 1.3 |
| Arm B: Fenofibrate | 0.3 |
Change in IL-6 from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 0.1 |
| Arm B: Fenofibrate | 0.2 |
Change in Large HDL Particles from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | nmol/L (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 0.9 |
| Arm B: Fenofibrate | -0.3 |
Change in LDL cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -1 |
| Arm B: Fenofibrate | 7 |
Change in non-HDL Cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -17 |
| Arm B: Fenofibrate | -4 |
Change in Small LDL particles from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | nmol/L (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -176 |
| Arm B: Fenofibrate | -119 |
Change in Triglycerides (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -65 |
| Arm B: Fenofibrate | -54 |
Among men, change in HDL Cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 3 |
| Arm B: Fenofibrate | 6.5 |
Among women, change in HDL cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 16 |
| Arm B: Fenofibrate | 8 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 547 |
| Standard Glycemia Control | 623 |
| Intensive Blood Pressure Control | 266 |
| Standard Blood Pressure Control | 300 |
| Fenofibrate + Simvastatin Therapy | 305 |
| Placebo + Simvastatin Therapy | 299 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 44 |
| Standard Glycemia Control | 40 |
| Intensive Blood Pressure Control | 18 |
| Standard Blood Pressure Control | 20 |
| Fenofibrate + Simvastatin Therapy | 24 |
| Placebo + Simvastatin Therapy | 22 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 744 |
| Standard Glycemia Control | 752 |
| Intensive Blood Pressure Control | 367 |
| Standard Blood Pressure Control | 382 |
| Fenofibrate + Simvastatin Therapy | 354 |
| Placebo + Simvastatin Therapy | 393 |
Diabetic retinopathy status was defined according to the eye with the highest level on the ETDRS Final Severity Scale for Persons, as follows: no diabetic retinopathy, a level of less than 20; mild diabetic retinopathy, a level of 20; moderate nonproliferative diabetic retinopathy (NPDR), a level above 20 but less than 53; severe diabetic retinopathy, a level of 53 but less than 60; and proliferative diabetic retinopathy (PDR), a level of 60 or higher. (NCT00542178)
Timeframe: Measured at Year 4
| Intervention | participants (Number) |
|---|---|
| Intensive Glycemia Control | 104 |
| Standard Glycemia Control | 149 |
| Intensive Blood Pressure Control | 67 |
| Standard Blood Pressure Control | 54 |
| Fenofibrate + Simvastatin Therapy | 52 |
| Placebo + Simvastatin Therapy | 80 |
[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | 14.0 |
| ABT-335 + 40 mg Atorvastatin | 12.6 |
| ABT-335 | 19.9 |
| 20 mg Atorvastatin | 6.3 |
| 40 mg Atorvastatin | 5.3 |
| 80 mg Atorvastatin | 6.2 |
[(Week 12 Apo B minus baseline Apo B)/baseline Apo B] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -37.0 |
| ABT-335 + 40 mg Atorvastatin | -37.1 |
| ABT-335 | -12.4 |
| 20 mg Atorvastatin | -32.9 |
| 40 mg Atorvastatin | -35.3 |
| 80 mg Atorvastatin | -40.3 |
[(Week 12 LDL-C minus baseline LDL-C)/baseline LDL-C] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -33.7 |
| ABT-335 + 40 mg Atorvastatin | -35.4 |
| ABT-335 | -3.4 |
| 20 mg Atorvastatin | -37.1 |
| 40 mg Atorvastatin | -39.7 |
| 80 mg Atorvastatin | -46.0 |
[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -40.8 |
| ABT-335 + 40 mg Atorvastatin | -42.5 |
| ABT-335 | -14.8 |
| 20 mg Atorvastatin | -35.7 |
| 40 mg Atorvastatin | -41.7 |
| 80 mg Atorvastatin | -45.2 |
[(Week 12 total cholesterol minus baseline total cholesterol)/baseline total cholesterol] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -32.8 |
| ABT-335 + 40 mg Atorvastatin | -34.6 |
| ABT-335 | -10.1 |
| 20 mg Atorvastatin | -29.6 |
| 40 mg Atorvastatin | -33.8 |
| 80 mg Atorvastatin | -38.2 |
[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -45.6 |
| ABT-335 + 40 mg Atorvastatin | -42.1 |
| ABT-335 | -29.6 |
| 20 mg Atorvastatin | -16.5 |
| 40 mg Atorvastatin | -23.2 |
| 80 mg Atorvastatin | -30.4 |
[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -48.3 |
| ABT-335 + 40 mg Atorvastatin | -53.5 |
| ABT-335 | -36.5 |
| 20 mg Atorvastatin | -26.2 |
| 40 mg Atorvastatin | -35.6 |
| 80 mg Atorvastatin | -38.9 |
[(Week 12 hsCRP minus baseline hsCRP)/baseline hsCRP] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Median) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -26.2 |
| ABT-335 + 40 mg Atorvastatin | -42.9 |
| ABT-335 | -12.4 |
| 20 mg Atorvastatin | -29.6 |
| 40 mg Atorvastatin | -30.3 |
| 80 mg Atorvastatin | -31.9 |
[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | 20.3 |
| ABT-335 + 20 mg Rosuvastatin | 19.0 |
| ABT-335 | 15.0 |
| 10 mg Rosuvastatin | 8.5 |
| 20 mg Rosuvastatin | 10.3 |
| 40 mg Rosuvastatin | 9.3 |
[(Week 12 Apo B minus baseline Apo B)/baseline Apo B] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -39.2 |
| ABT-335 + 20 mg Rosuvastatin | -39.2 |
| ABT-335 | -16.2 |
| 10 mg Rosuvastatin | -34.1 |
| 20 mg Rosuvastatin | -39.6 |
| 40 mg Rosuvastatin | -45.0 |
[(Week 12 LDL-C minus baseline LDL-C)/baseline LDL-C] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -37.2 |
| ABT-335 + 20 mg Rosuvastatin | -38.8 |
| ABT-335 | -6.5 |
| 10 mg Rosuvastatin | -38.0 |
| 20 mg Rosuvastatin | -45.0 |
| 40 mg Rosuvastatin | -50.6 |
[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -44.7 |
| ABT-335 + 20 mg Rosuvastatin | -45.3 |
| ABT-335 | -18.5 |
| 10 mg Rosuvastatin | -39.8 |
| 20 mg Rosuvastatin | -45.8 |
| 40 mg Rosuvastatin | -51.5 |
[(Week 12 total cholesterol minus baseline total cholesterol)/baseline total cholesterol] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -34.4 |
| ABT-335 + 20 mg Rosuvastatin | -35.7 |
| ABT-335 | -13.5 |
| 10 mg Rosuvastatin | -32.5 |
| 20 mg Rosuvastatin | -37.3 |
| 40 mg Rosuvastatin | -42.7 |
[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -47.1 |
| ABT-335 + 20 mg Rosuvastatin | -42.9 |
| ABT-335 | -32.6 |
| 10 mg Rosuvastatin | -24.4 |
| 20 mg Rosuvastatin | -25.6 |
| 40 mg Rosuvastatin | -32.1 |
[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -55.8 |
| ABT-335 + 20 mg Rosuvastatin | -50.6 |
| ABT-335 | -31.9 |
| 10 mg Rosuvastatin | -41.0 |
| 20 mg Rosuvastatin | -42.1 |
| 40 mg Rosuvastatin | -49.1 |
[(Week 12 hsCRP minus baseline hsCRP)/baseline hsCRP] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Median) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -33.8 |
| ABT-335 + 20 mg Rosuvastatin | -40.8 |
| ABT-335 | -12.1 |
| 10 mg Rosuvastatin | -22.9 |
| 20 mg Rosuvastatin | -29.9 |
| 40 mg Rosuvastatin | -33.1 |
[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | 17.8 |
| ABT-335 + 40 mg Simvastatin | 18.9 |
| ABT-335 | 16.2 |
| 20 mg Simvastatin | 7.2 |
| 40 mg Simvastatin | 8.5 |
| 80 mg Simvastatin | 6.8 |
[(Week 12 Apo B minus baseline Apo B)/baseline Apo B] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -29.5 |
| ABT-335 + 40 mg Simvastatin | -31.2 |
| ABT-335 | -17.6 |
| 20 mg Simvastatin | -22.9 |
| 40 mg Simvastatin | -32.7 |
| 80 mg Simvastatin | -38.9 |
[(Week 12 LDL-C minus baseline LDL-C)/baseline LDL-C] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -24.0 |
| ABT-335 + 40 mg Simvastatin | -25.3 |
| ABT-335 | -4.0 |
| 20 mg Simvastatin | -22.4 |
| 40 mg Simvastatin | -31.7 |
| 80 mg Simvastatin | -40.8 |
[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -30.7 |
| ABT-335 + 40 mg Simvastatin | -35.0 |
| ABT-335 | -17.3 |
| 20 mg Simvastatin | -24.4 |
| 40 mg Simvastatin | -35.9 |
| 80 mg Simvastatin | -40.6 |
[(Week 12 total cholesterol minus baseline total cholesterol)/baseline total cholesterol] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -23.9 |
| ABT-335 + 40 mg Simvastatin | -27.1 |
| ABT-335 | -12.4 |
| 20 mg Simvastatin | -19.8 |
| 40 mg Simvastatin | -30.0 |
| 80 mg Simvastatin | -33.6 |
[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -37.4 |
| ABT-335 + 40 mg Simvastatin | -42.7 |
| ABT-335 | -31.7 |
| 20 mg Simvastatin | -14.2 |
| 40 mg Simvastatin | -22.4 |
| 80 mg Simvastatin | -20.2 |
[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -38.9 |
| ABT-335 + 40 mg Simvastatin | -51.1 |
| ABT-335 | -36.9 |
| 20 mg Simvastatin | -19.2 |
| 40 mg Simvastatin | -35.7 |
| 80 mg Simvastatin | -30.0 |
[(Week 12 hsCRP minus baseline hsCRP)/baseline hsCRP] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Median) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -26.8 |
| ABT-335 + 40 mg Simvastatin | -32.1 |
| ABT-335 | -15.8 |
| 20 mg Simvastatin | -11.4 |
| 40 mg Simvastatin | -14.8 |
| 80 mg Simvastatin | -19.8 |
(NCT00300430)
Timeframe: Baseline to Week 52 of the open-label study
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | -44.8 |
| ABT-335 + 40 mg Simvastatin | -35.5 |
| ABT-335 + 40 mg Atorvastatin | -42.9 |
(NCT00300430)
Timeframe: Baseline to Week 52 of the open-label study
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | -41.6 |
| ABT-335 + 40 mg Simvastatin | -30.2 |
| ABT-335 + 40 mg Atorvastatin | -38.1 |
(NCT00300430)
Timeframe: Baseline to Week 52 of the open-label study
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | 25.2 |
| ABT-335 + 40 mg Simvastatin | 25.1 |
| ABT-335 + 40 mg Atorvastatin | 19.4 |
(NCT00300430)
Timeframe: Baseline to Week 52 in this open-label study
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | -48.8 |
| ABT-335 + 40 mg Simvastatin | -36.6 |
| ABT-335 + 40 mg Atorvastatin | -44.3 |
(NCT00300430)
Timeframe: Baseline to Week 52 of the open-label study
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | -37.9 |
| ABT-335 + 40 mg Simvastatin | -27.5 |
| ABT-335 + 40 mg Atorvastatin | -35.0 |
(NCT00300430)
Timeframe: Baseline to Week 52 of the open-label study
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | -56.9 |
| ABT-335 + 40 mg Simvastatin | -37.7 |
| ABT-335 + 40 mg Atorvastatin | -52.2 |
(NCT00300430)
Timeframe: Baseline to Week 52 of the open-label study
| Intervention | percent change (Median) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | -38.87 |
| ABT-335 + 40 mg Simvastatin | -27.72 |
| ABT-335 + 40 mg Atorvastatin | -39.13 |
(NCT00300430)
Timeframe: Baseline to Week 52 of the open-label study
| Intervention | percent change (Median) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | -53.0 |
| ABT-335 + 40 mg Simvastatin | -47.7 |
| ABT-335 + 40 mg Atorvastatin | -56.2 |
(NCT00300430)
Timeframe: Anytime after initiation of combination therapy (either in the double-blind or open-label study) to within 30 days after the last dose of combination therapy
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | 83 |
| ABT-335 + 40 mg Simvastatin | 86 |
| ABT-335 + 40 mg Atorvastatin | 85 |
[(Week 104 LDL-C minus baseline LDL-C)/baseline LDL-C] X 100. Baseline is the last value prior to the first dose of combination therapy. (NCT00491530)
Timeframe: Baseline to Week 104 (may include weeks in preceding double-blind studies [combination treatment arms], plus 52 weeks in preceding open-label year 1 study, and open-label year 2 study, up to 104 weeks)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | -19.2 |
| ABT-335 + 40 mg Simvastatin | -20.2 |
| ABT-335 + 40 mg Atorvastatin | -20.5 |
[(Week 104 HDL-C minus baseline HDL-C)/baseline HDL-C] X 100. Baseline is the last value prior to the first dose of combination therapy. (NCT00491530)
Timeframe: Baseline to Week 104 (may include weeks in preceding double-blind studies [combination treatment arms], plus 52 weeks in preceding open-label year 1 study, and open-label year 2 study, up to 104 weeks)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | 13.7 |
| ABT-335 + 40 mg Simvastatin | 11.2 |
| ABT-335 + 40 mg Atorvastatin | 5.2 |
[(Week 104 Non-HDL-C minus baseline Non-HDL-C)/baseline Non-HDL-C] X 100. Baseline is the last value prior to the first dose of combination therapy. (NCT00491530)
Timeframe: Baseline to Week 104 (may include weeks in preceding double-blind studies [combination treatment arms], plus 52 weeks in preceding open-label year 1 study, and open-label year 2 study, up to 104 weeks)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | -26.9 |
| ABT-335 + 40 mg Simvastatin | -23.8 |
| ABT-335 + 40 mg Atorvastatin | -25.1 |
[(Week 104 Total-C minus baseline Total-C)/baseline Total-C] X 100. Baseline is the last value prior to the first dose of combination therapy. (NCT00491530)
Timeframe: Baseline to Week 104 (may include weeks in preceding double-blind studies [combination treatment arms], plus 52 weeks in preceding open-label year 1 study, and open-label year 2 study, up to 104 weeks)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | -20.1 |
| ABT-335 + 40 mg Simvastatin | -17.9 |
| ABT-335 + 40 mg Atorvastatin | -20.4 |
[(Week 104 VLDL-C minus baseline VLDL-C)/baseline VLDL-C] X 100. Baseline is the last value prior to the first dose of combination therapy. (NCT00491530)
Timeframe: Baseline to Week 104 (may include weeks in preceding double-blind studies [combination treatment arms], plus 52 weeks in preceding open-label year 1 study, and open-label year 2 study, up to 104 weeks)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | -33.7 |
| ABT-335 + 40 mg Simvastatin | -18.7 |
| ABT-335 + 40 mg Atorvastatin | -26.6 |
[(Week 104 triglycerides minus baseline triglycerides)/baseline triglycerides] X 100. Baseline is the last value prior to the first dose of combination therapy. (NCT00491530)
Timeframe: Baseline to Week 104 (may include weeks in preceding double-blind studies [combination treatment arms], plus 52 weeks in preceding open-label year 1 study, and open-label year 2 study, up to 104 weeks)
| Intervention | percent change (Median) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | -36.9 |
| ABT-335 + 40 mg Simvastatin | -29.6 |
| ABT-335 + 40 mg Atorvastatin | -38.7 |
All serious and non-serious adverse events are reported from the time of combination study drug initiation until 30 days after discontinuation of study drug. Adverse events are unfavorable changes in health that occur in subjects during a clinical trial or within a specified period following a trial. Serious adverse events are those that result in death, require inpatient hospitalization or the prolongation of hospitalization, result in congenital anomaly/birth defect, or significant disability/incapacity or are life-threatening. (NCT00491530)
Timeframe: Anytime after initiation of combination therapy (in the preceding 12-week double-blind studies or in the preceding open-label year 1 study) up to 116 weeks, to within 30 days after the last dose of combination therapy.
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-335 + 20 mg Rosuvastatin | 94.8 |
| ABT-335 + 40 mg Simvastatin | 90.0 |
| ABT-335 + 40 mg Atorvastatin | 97.7 |
Mean percent change from baseline to end-of-treatment (12 weeks) for non-HDL cholesterol and triglycerides and the mean percent change from baseline to end-of-treatment for HDL cholesterol for AtorFen 40/100mg fixed-dose combination tablet versus atorvastatin 40mg tablet. (NCT00504829)
Timeframe: baseline(randomization) to 12 weeks
| Intervention | percent change from baseline (Mean) | ||
|---|---|---|---|
| non-HDL | triglycerides | HDL | |
| Atorvastatin 40mg | -40.2 | -28.9 | 6.5 |
| LCP-AtorFen 40/100mg | -44.8 | -49.1 | 19.7 |
Mean percent changes from baseline (Visit 3, Week 0) to end-of-treatment (Visit 6; Week 12) in non-HDL, HDL and LDL cholesterol by LCP-AtorFen versus fenofibrate monotherapy (NCT00504829)
Timeframe: baseline (week 0) to 12 weeks
| Intervention | percent change from baseline (Mean) | ||
|---|---|---|---|
| non-HDL | LDL | HDL | |
| Fenofibrate 145mg | -16.1 | -13.9 | 18.2 |
| LCP-AtorFen 40/100mg | -44.8 | -42.3 | 19.7 |
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
[(Week 12 apoAI minus baseline apoAI)/baseline apoAI] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)
| Intervention | Percent change (Mean) |
|---|---|
| ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe | 1.8 |
| Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe | -1.3 |
[(Week 12 apoB minus baseline apoB)/baseline apoB] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)
| Intervention | Percent change (Mean) |
|---|---|
| ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe | -49.1 |
| Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe | -44.7 |
[(Week 12 apoCIII minus baseline apoCIII)/baseline apoCIII] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)
| Intervention | Percent change (Mean) |
|---|---|
| ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe | -42.5 |
| Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe | -25.3 |
[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)
| Intervention | Percent change (Mean) |
|---|---|
| ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe | 13.0 |
| Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe | 4.2 |
[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)
| Intervention | Percent change (Mean) |
|---|---|
| ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe | -55.6 |
| Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe | -51.0 |
[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (final visit)
| Intervention | Percent change (Mean) |
|---|---|
| ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe | -57.8 |
| Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe | -41.1 |
[(Week 12 hsCRP minus baseline hsCRP)/baseline hSCRP] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)
| Intervention | Percent change (Median) |
|---|---|
| ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe | -52.1 |
| Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe | -40.3 |
[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides] x 100 (NCT00639158)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | Percent change (Median) |
|---|---|
| ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe | -57.3 |
| Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe | -39.7 |
The mean percent change from baseline to the final visit in apolipoprotein B (ApoB), with ABT-335 135 mg in combination with rosuvastatin 5 mg versus rosuvastatin 5 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -30.9 |
| Rosuvastatin Calcium | -26.4 |
The mean percent change from baseline to the final visit in High-density lipoprotein cholesterol (HDL-C), with ABT-335 135 mg in combination with rosuvastatin 5 mg versus rosuvastatin 5 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | 23.0 |
| Rosuvastatin Calcium | 12.4 |
The mean percent change from baseline to the final visit in low-density lipoprotein cholesterol (LDL-C), with ABT-335 135 mg in combination with rosuvastatin 5 mg versus ABT-335 135 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -28.7 |
| ABT-335 | -4.1 |
The mean percent change from baseline to the final visit in non-high-density lipoprotein cholesterol (non-HDL-C), with ABT-335 135 mg in combination with rosuvastatin 5 mg versus ABT-335 135 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -37.4 |
| ABT-335 | -16.0 |
The mean percent change from baseline to the final visit in non-high-density lipoprotein cholesterol (non-HDL-C), with ABT-335 135 mg in combination with rosuvastatin 5 mg versus rosuvastatin 5 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -37.4 |
| Rosuvastatin Calcium | -31.8 |
The mean percent change from baseline to the final visit in total cholesterol, with ABT-335 135 mg in combination with rosuvastatin 5 mg versus rosuvastatin 5 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -28.1 |
| Rosuvastatin Calcium | -25.0 |
The mean percent change from baseline to the final visit in triglycerides, with ABT-335 135 mg in combination with rosuvastatin 5 mg versus rosuvastatin 5 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -40.3 |
| Rosuvastatin Calcium | -17.5 |
The mean percent change from baseline to the final visit in very-low-density lipoprotein cholesterol (VLDL-C), with ABT-335 135 mg in combination with rosuvastatin 5 mg versus rosuvastatin 5 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -41.3 |
| Rosuvastatin Calcium | -22.2 |
The median percent change from baseline to the final visit in high sensitivity C-reactive protein (hsCRP), with ABT-335 135 mg in combination with rosuvastatin 5 mg versus rosuvastatin 5 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Median) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -28.0 |
| Rosuvastatin Calcium | -11.4 |
HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| Group 1 - Usual Care | 37.1 |
| Group 2 - Diet/Exercise Only | 38.7 |
| Group 3 - Diet/Exercise + Fenofibrate | 40.7 |
| Group 4 - Diet/Exercise + Niacin | 41.8 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 44.8 |
non-HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| Group 1 - Usual Care | 162.2 |
| Group 2 - Diet/Exercise Only | 165.4 |
| Group 3 - Diet/Exercise + Fenofibrate | 145.8 |
| Group 4 - Diet/Exercise + Niacin | 154 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 137.1 |
Total cholesterol (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Group 1 - Usual Care | 195.6 |
| Group 2 - Diet/Exercise Only | 200.1 |
| Group 3 - Diet/Exercise + Fenofibrate | 184 |
| Group 4 - Diet/Exercise + Niacin | 190.8 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 178.4 |
Total cholesterol : HDL-C ratio: Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | ratio (Mean) |
|---|---|
| Group 1 - Usual Care | 5.2 |
| Group 2 - Diet/Exercise Only | 5.1 |
| Group 3 - Diet/Exercise + Fenofibrate | 4.5 |
| Group 4 - Diet/Exercise + Niacin | 4.6 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 4 |
Triglycerides (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Group 1 - Usual Care | 199 |
| Group 2 - Diet/Exercise Only | 216.9 |
| Group 3 - Diet/Exercise + Fenofibrate | 155.1 |
| Group 4 - Diet/Exercise + Niacin | 177.6 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 135.6 |
"Body cell mass (kg)~Fat mass (kg)" (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Body cell mass | Fat mass | |
| Group 1 - Usual Care | 59.6 | 36.8 |
| Group 2 - Diet/Exercise | 67.3 | 37.5 |
| Group 3 - Diet/Exercise + Fenofibrate | 66.6 | 35.8 |
| Group 4 - Diet/Exercise + Niacin | 67.1 | 37.7 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 68.2 | 36.2 |
Adiponectin (micrograms/ml) (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | micrograms/ml (Mean) | |||
|---|---|---|---|---|
| Fasting insulin | HOMA-IR | Insulin sensitvity index | Adiponectin | |
| Group 1 - Usual Care | 8.7 | 1.92 | 3.54 | 7.12 |
| Group 2 - Diet/Exercise Only | 6.7 | 1.38 | 4.95 | 6.04 |
| Group 3 - Diet/Exercise + Fenofibrate | 9.5 | 2.02 | 3.81 | 5.24 |
| Group 4 - Diet/Exercise + Niacin | 11.9 | 2.76 | 2.88 | 11.01 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 10.3 | 2.38 | 2.38 | 10.34 |
Rate of change (mm/year) from baseline in composite of mean of maximal posterior-wall and anterior-wall intima-media thickness (IMT) of the left and right common carotid artery, internal carotid artery, and carotid bifurcation. The statistical model used change from baseline as the dependent variable, with time of IMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. IMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months
| Intervention | mm/year (Mean) |
|---|---|
| ABT-335 + Atorvastatin | -0.003 |
| Placebo + Atorvastatin | -0.019 |
Rate of change (mm/year) from baseline in composite of mean of maximal posterior-wall intima-media thickness (IMT) of the left and right common carotid artery, internal carotid artery, and carotid bifurcation. The statistical model used change from baseline as the dependent variable, with time of IMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. IMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months
| Intervention | mm/year (Mean) |
|---|---|
| ABT-335 + Atorvastatin | -0.014 |
| Placebo + Atorvastatin | -0.008 |
Rate of change (mm/year) from baseline in composite of mean of the mean posterior-wall intima-media thickness (IMT) of the left and right common carotid artery, internal carotid artery, and carotid bifurcation. The statistical model used change from baseline as the dependent variable, with time of IMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. IMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months
| Intervention | mm/year (Mean) |
|---|---|
| ABT-335 + Atorvastatin | -0.010 |
| Placebo + Atorvastatin | -0.004 |
Rate of change (mm/year) from baseline in mean of maximal posterior-wall carotid intima-media thickness (cIMT) of the left and right common carotid artery. The statistical model used change from baseline as the dependent variable, with time of cIMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. cIMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months
| Intervention | mm/year (Mean) |
|---|---|
| ABT-335 + Atorvastatin | -0.005 |
| Placebo + Atorvastatin | -0.003 |
Rate of change (mm/year) from baseline in mean of posterior-wall carotid intima-media thickness (cIMT) of the left and right common carotid artery. The statistical model used change from baseline as the dependent variable, with time of cIMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. cIMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months
| Intervention | mm/year (Mean) |
|---|---|
| ABT-335 + Atorvastatin | -0.006 |
| Placebo + Atorvastatin | 0.000 |
53 reviews available for fenofibrate and Dyslipidemias
| Article | Year |
|---|---|
Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review.
Topics: Butyrates; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Netw | 2023 |
SPPARM alpha: the Lazarus effect.
Topics: Animals; Atherosclerosis; Benzoxazoles; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofib | 2019 |
Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate.
Topics: Benzoxazoles; Butyrates; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents; Randomized Contro | 2019 |
Control of the overall lipid profile.
Topics: Apolipoproteins B; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemi | 2019 |
Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Topics: Animals; Atherosclerosis; Benzoxazoles; Butyrates; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug | 2020 |
Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Glucagon-Like Peptid | 2017 |
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hy | 2018 |
Fenofibrate and Dyslipidemia: Still a Place in Therapy?
Topics: Cardiovascular Diseases; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents; Risk Factors; Tre | 2018 |
Molecular targets of fenofibrate in the cardiovascular-renal axis: A unifying perspective of its pleiotropic benefits.
Topics: Animals; Cardiovascular Diseases; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents; Kidney D | 2019 |
Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials.
Topics: Adiponectin; Dyslipidemias; Fenofibrate; Gene Expression Regulation; Humans; Hypolipidemic Agents; I | 2013 |
Summarizing the FIELD study: lessons from a 'negative' trial.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Hypolipidemi | 2013 |
[Impact of dyslipidemia on the onset and progression of diabetic complications].
Topics: Cerebrovascular Disorders; Coronary Disease; Diabetic Angiopathies; Diabetic Nephropathies; Dyslipid | 2013 |
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofib | 2014 |
Safety considerations with fenofibrate/simvastatin combination.
Topics: Drug Combinations; Drug Interactions; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA | 2015 |
[What is the contribution of the review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidemia? Report on consensus of experts in the importance of the combined therapy by fenofibrate with statin].
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents | 2015 |
[Diabetic dyslipidaemia and the atherosclerosis].
Topics: Apolipoprotein A-V; Apolipoproteins A; Apolipoproteins C; Atherosclerosis; Cardiovascular Diseases; | 2016 |
Fenofibrate and Diabetic Retinopathy.
Topics: Diabetic Retinopathy; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibi | 2016 |
Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.
Topics: Animals; Biomarkers; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-Co | 2017 |
Fenofibrate: treatment of hyperlipidemia and beyond.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Dyslipidemias; Fenofibrate; Humans; Hypo | 2008 |
Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dys | 2008 |
More clinical lessons from the FIELD study.
Topics: Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; | 2009 |
Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality?
Topics: Diabetic Retinopathy; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibi | 2009 |
Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.
Topics: Cardiovascular Diseases; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethy | 2008 |
Advances in the medical treatment of diabetic retinopathy.
Topics: Blindness; Blood-Retinal Barrier; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Dia | 2009 |
Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Delayed-Action Preparations; Drug Delivery Systems; Dysli | 2010 |
Management of dyslipidemia in people with type 2 diabetes mellitus.
Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ez | 2010 |
Fenofibrate, homocysteine and renal function.
Topics: Animals; Biomarkers; Creatinine; Disease Progression; Dyslipidemias; Fenofibrate; Glomerular Filtrat | 2010 |
Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia.
Topics: Delayed-Action Preparations; Drug Approval; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; H | 2010 |
Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
Topics: Anti-HIV Agents; Cholesterol, HDL; Coronary Disease; Dyslipidemias; Fenofibrate; HIV Infections; Hum | 2010 |
Lipid disorders in type 2 diabetes.
Topics: Atherosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Hu | 2009 |
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Delayed-Action Preparations; Drug Interactions; Drug Ther | 2010 |
[The significance of fenofibrate in the therapy of atherogenic dyslipoproteinaemia].
Topics: Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents; Lipoproteins, LDL | 2010 |
The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.
Topics: Choline; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; H | 2010 |
Pleiotropic actions of fenofibrate on the heart.
Topics: Animals; Dyslipidemias; Fenofibrate; Heart; Heart Diseases; Humans; Hypolipidemic Agents; Treatment | 2011 |
Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Fenofibrate; Humans; Hypol | 2011 |
Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.
Topics: Adult; Cardiovascular Diseases; Diabetes Complications; Drug Combinations; Drug Monitoring; Dyslipid | 2011 |
Fenofibrate: a review of its use in dyslipidaemia.
Topics: Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents; Treatment Outcome | 2011 |
[Perspectives of the use of fenofibrate in patients with type 2 diabetes mellitus: what is new after the ACCORD Study?].
Topics: Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Human | 2011 |
Do persons with diabetes benefit from combination statin and fibrate therapy?
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Female; | 2012 |
Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?
Topics: Animals; Diabetes Mellitus; Diabetic Nephropathies; Dyslipidemias; Fenofibrate; Humans; Hypolipidemi | 2012 |
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.
Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fluorobenzenes; Heptanoic Acids | 2012 |
Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Creatine Kinase; Drug Therapy, Combination; Dysli | 2013 |
Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials.
Topics: Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase I | 2013 |
A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Topics: Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents | 2005 |
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diet; Drug T | 2005 |
Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Dose-Response Relationship, Dru | 2005 |
FIELD study.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic | 2006 |
Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents; Metabolic Syndr | 2007 |
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
Topics: Bezafibrate; Clofibric Acid; Dyslipidemias; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipi | 2007 |
Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.
Topics: Animals; Capsules; Computer Simulation; Drug Compounding; Dyslipidemias; Fenofibrate; Humans; Lipid | 2006 |
Is it time to stop treating dyslipidaemia with fibrates?
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Clofibric Acid; Dia | 2007 |
Combination of a sterol absorption inhibitor and cardiovascular agents for the treatment of dyslipidemia.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials a | 2006 |
Combination therapy in the management of mixed dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Routes; Dr | 2008 |
85 trials available for fenofibrate and Dyslipidemias
| Article | Year |
|---|---|
Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Drug Therapy, | 2020 |
Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFE
Topics: Adult; Aged; Aged, 80 and over; Coronary Artery Disease; Drug Therapy, Combination; Dyslipidemias; F | 2020 |
Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.
Topics: Aged; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; | 2020 |
Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Female; Feno | 2018 |
Efficacy and Safety of Policosanol Plus Fenofibrate Combination Therapy in Elderly Patients with Mixed Dyslipidemia: A Randomized, Controlled Clinical Study.
Topics: Aged; Aged, 80 and over; Ankle Brachial Index; Dyslipidemias; Fatty Alcohols; Female; Fenofibrate; H | 2018 |
Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia.
Topics: Cholesterol, HDL; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Dysli | 2013 |
Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoproteins B; Atherosclerosis; C-R | 2013 |
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Chole | 2013 |
Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue.
Topics: 3T3-L1 Cells; Adipocytes; Adult; Animals; Disease Models, Animal; Dyslipidemias; Fenofibrate; Humans | 2014 |
Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions.
Topics: Aged; Blood Chemical Analysis; Delayed-Action Preparations; Dose-Response Relationship, Drug; Dyslip | 2013 |
Xanthophylls, phytosterols and pre-β1-HDL are differentially affected by fenofibrate and niacin HDL-raising in a cross-over study.
Topics: Apolipoprotein A-II; Cross-Over Studies; Dyslipidemias; Female; Fenofibrate; High-Density Lipoprotei | 2013 |
Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Doub | 2014 |
Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
Topics: Adult; Atorvastatin; Cholesterol; Cost-Benefit Analysis; Drug Administration Schedule; Drug Combinat | 2014 |
Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dise | 2014 |
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combinatio | 2014 |
Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.
Topics: Apolipoprotein B-100; Apolipoprotein C-III; Biomarkers; Cholesterol, HDL; Double-Blind Method; Drug | 2014 |
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
Topics: Atorvastatin; Carotid Intima-Media Thickness; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; | 2014 |
Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.
Topics: Adult; Anticholesteremic Agents; Azetidines; Drug-Related Side Effects and Adverse Reactions; Dyslip | 2014 |
Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia.
Topics: Aged; Apoptosis; Biomarkers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidem | 2015 |
Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
Topics: Adult; Aged; Antioxidants; Biomarkers; Cholesterol, HDL; Cross-Sectional Studies; Diabetes Mellitus, | 2015 |
Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.
Topics: Adult; Brachial Artery; C-Reactive Protein; Cholesterol, HDL; Delayed-Action Preparations; Dyslipide | 2015 |
New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies.
Topics: Aged; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cystatin C; Double-Blind Method; Drug Combin | 2015 |
Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy.
Topics: Aged; Australia; Brachial Artery; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; End | 2015 |
Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Biomarkers; Blood Glucose; Canada; Card | 2016 |
Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Benzoxazoles; Butyrates; Cardiovascular Diseases; Cholesterol, LDL; | 2016 |
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Re | 2016 |
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Re | 2016 |
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Re | 2016 |
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Re | 2016 |
Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment.
Topics: Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrat | 2016 |
Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2017 |
Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
Topics: Adult; Apolipoprotein C-III; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol; Cross- | 2008 |
Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects.
Topics: Adult; Aged; Blood Glucose; Caloric Restriction; Cardiovascular Diseases; Cholesterol; Dyslipidemias | 2008 |
Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein B-100; C-Reactive Protein; Cholesterol, HDL; Diabete | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; F | 2008 |
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Hypo | 2009 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Doubl | 2009 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Doubl | 2009 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Doubl | 2009 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Doubl | 2009 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Femal | 2009 |
Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue.
Topics: 3T3-L1 Cells; Adiponectin; Adipose Tissue; Adult; Animals; Diabetes Mellitus, Type 2; Down-Regulatio | 2009 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Double-Blin | 2009 |
Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
Topics: Apolipoprotein A-I; Apolipoprotein A-II; Australia; Biomarkers; Cholesterol, HDL; Creatinine; Diabet | 2009 |
Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Combined Modality Therapy; Cytokines; Di | 2009 |
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients.
Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Fem | 2009 |
Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study.
Topics: Adipokines; Adult; Aged; Azetidines; Body Mass Index; Diet, Reducing; Drug Therapy, Combination; Dys | 2010 |
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, C | 2010 |
Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Chol | 2009 |
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Disea | 2009 |
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Disea | 2009 |
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Disea | 2009 |
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Disea | 2009 |
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Disea | 2009 |
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Disea | 2009 |
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Disea | 2009 |
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Disea | 2009 |
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Disea | 2009 |
A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Dyslipidemias; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA R | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabe | 2010 |
Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angio | 2010 |
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Dos | 2010 |
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Dos | 2010 |
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Dos | 2010 |
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Dos | 2010 |
Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therap | 2010 |
Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.
Topics: Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrat | 2010 |
Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Follow-Up St | 2010 |
Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; | 2011 |
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, | 2011 |
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, | 2011 |
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, | 2011 |
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, | 2011 |
Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Topics: Adult; Aged; Analysis of Variance; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Hu | 2011 |
High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia.
Topics: Dyslipidemias; Fatty Acids, Omega-3; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agen | 2011 |
Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis.
Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptano | 2011 |
The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses.
Topics: Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Male; Placebo Effect; Simvast | 2011 |
Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.
Topics: Adiponectin; Adult; Aged; Anti-Retroviral Agents; Double-Blind Method; Dyslipidemias; Exercise; Fema | 2011 |
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Aryldialkylphosphatase; C-Reactive Prot | 2011 |
[Possibilities of improvement of prognosis in patients with type 2 diabetes mellitus after coronary interventions].
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Corona | 2011 |
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
Topics: Apolipoprotein A-I; Apolipoprotein A-V; Apolipoproteins A; Biomarkers; Cholesterol, HDL; Double-Blin | 2011 |
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Co | 2011 |
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Co | 2011 |
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Co | 2011 |
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Co | 2011 |
LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
Topics: Apolipoprotein C-III; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofib | 2012 |
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Dose-Response Relationship, Drug; Double-B | 2012 |
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Dose-Response Relationship, Drug; Double-B | 2012 |
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Dose-Response Relationship, Drug; Double-B | 2012 |
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Dose-Response Relationship, Drug; Double-B | 2012 |
Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment.
Topics: Adult; Aged; Analysis of Variance; Apolipoprotein B-48; Apolipoprotein C-III; Brachial Artery; Chole | 2012 |
Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels.
Topics: 25-Hydroxyvitamin D 2; Adult; Aged; Calcifediol; Cardiovascular Diseases; Combined Modality Therapy; | 2012 |
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Carotid Intima-Me | 2012 |
Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angiopoietins; Apolipoproteins; Apolipoprot | 2012 |
Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.
Topics: Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Fatty | 2012 |
The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitus.
Topics: Adult; CD11a Antigen; CD18 Antigens; Cross-Over Studies; Diabetes Mellitus, Type 2; Dyslipidemias; F | 2012 |
Fenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor α-dependent and independent mechanisms in human endothelial cells.
Topics: Apoptosis Regulatory Proteins; Binding Sites; Brachial Artery; Cell Cycle Proteins; Cell Line; Diabe | 2013 |
The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellit | 2006 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity.
Topics: Dyslipidemias; Female; Fenofibrate; Glutathione Peroxidase; Humans; Hypolipidemic Agents; Lipids; Li | 2006 |
[Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes].
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Hypoli | 2005 |
Field of confusion: future prospects for fibrate therapy in cardiovascular disease.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Diabetes Mellitus, Type 2; Double-Blind | 2006 |
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
Topics: Anti-Obesity Agents; Atorvastatin; Diet, Fat-Restricted; Drug Therapy, Combination; Dyslipidemias; F | 2006 |
Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects.
Topics: Adult; Aged; Atherosclerosis; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fenofibr | 2006 |
The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Di | 2006 |
[The anti-inflammatory and antioxidants effects of micronized fenofibrate in patients with visceral obesity and dyslipidemia].
Topics: Adult; Anti-Inflammatory Agents; Antioxidants; C-Reactive Protein; Dyslipidemias; Erythrocyte Membra | 2006 |
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydr | 2007 |
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydr | 2007 |
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydr | 2007 |
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydr | 2007 |
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; | 2007 |
Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fe | 2008 |
91 other studies available for fenofibrate and Dyslipidemias
| Article | Year |
|---|---|
Design and synthesis of potent and subtype-selective PPARalpha agonists.
Topics: Animals; Cricetinae; Dogs; Drug Design; Dyslipidemias; Haplorhini; Hypolipidemic Agents; Molecular S | 2006 |
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
Topics: Animals; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Crystallography, X-Ray; Dogs; Dysl | 2007 |
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
Topics: Animals; Blood Glucose; Butyric Acid; Cell Line; Cholesterol; Cricetinae; Diabetes Mellitus, Type 2; | 2009 |
Synthesis and antidyslipidemic activity of chalcone fibrates.
Topics: Animals; Chalcone; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemi | 2011 |
Novel indole and triazole based hybrid molecules exhibit potent anti-adipogenic and antidyslipidemic activity by activating Wnt3a/β-catenin pathway.
Topics: 3T3-L1 Cells; Adipogenesis; Animals; Biological Transport; Cholesterol; Cricetinae; Drug Design; Dys | 2018 |
Pregnane-Oximino-Alkyl-Amino-Ether Compound as a Novel Class of TGR5 Receptor Agonist Exhibiting Antidiabetic and Anti-Dyslipidemic Activities.
Topics: Animals; Blood Glucose; Cell Line; Cricetinae; Diabetes Mellitus, Experimental; Dyslipidemias; Fenof | 2022 |
Prognostic significance of visit-to-visit variability, and maximum and minimum LDL cholesterol in diabetes mellitus.
Topics: Cholesterol; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Female; F | 2022 |
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Topics: Benzoxazoles; Bezafibrate; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; | 2022 |
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Topics: Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Cost-Benefit Analysis; Dyslipidemias; Ei | 2022 |
Macroprolactinaemia modulates cardiometabolic effects of fenofibrate in men with atherogenic dyslipidaemia: A pilot study.
Topics: Adult; Atherosclerosis; Case-Control Studies; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agen | 2020 |
[Molecular mechanisms of the cytoprotector cramizol effect in the experimental dyslipidemia model].
Topics: Animals; Cholesterol, HDL; Dyslipidemias; Fenofibrate; Hyperlipidemias; Hypolipidemic Agents; Rats; | 2020 |
The impact of vitamin D status on cardiometabolic effects of fenofibrate in women with atherogenic dyslipidemia.
Topics: Adult; Dyslipidemias; Female; Fenofibrate; Humans; Male; Middle Aged | 2021 |
Fenofibrate Regulates Visceral Obesity and Nonalcoholic Steatohepatitis in Obese Female Ovariectomized C57BL/6J Mice.
Topics: Adipocytes; Animals; Diet, High-Fat; Drug Evaluation, Preclinical; Dyslipidemias; Fatty Liver; Femal | 2021 |
Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.
Topics: Aldehyde Reductase; Animals; beta Karyopherins; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fe | 2018 |
Fenofibrate decreases the bone quality by down regulating Runx2 in high-fat-diet induced Type 2 diabetes mellitus mouse model.
Topics: Animals; Bone Density; Caspase 3; Collagen Type I; Core Binding Factor Alpha 1 Subunit; Diabetes Mel | 2017 |
Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans | 2018 |
Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy.
Topics: Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; | 2018 |
[THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Therapy, Combination; Dysl | 2018 |
Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia.
Topics: Adult; Age Factors; Biomarkers; Bromocriptine; Cardiovascular Diseases; Case-Control Studies; Dopami | 2019 |
Association between venous thromboembolism events and fibrates: A comparative study.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Databases, Factual; Diabetes Mellitus; Dyslipi | 2019 |
[Fibric acid derivatives: focus on fenofibrate].
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hypolipidem | 2013 |
Comparison of therapeutic lipid target achievements among high-risk patients in Oman.
Topics: Aged; Apolipoproteins; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coro | 2014 |
Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.
Topics: Amino Acids; Apolipoprotein A-I; Apolipoprotein A-V; Apolipoproteins A; Cholesterol, HDL; Dyslipidem | 2013 |
Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Topics: Adult; Aged; Asymptomatic Diseases; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Cohort S | 2013 |
Baseline very low-density lipoprotein cholesterol is associated with the magnitude of triglyceride lowering on statins, fenofibric acid, or their combination in patients with mixed dyslipidemia.
Topics: Analysis of Variance; Biomarkers; Cholesterol, VLDL; Down-Regulation; Drug Therapy, Combination; Dys | 2014 |
Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1α in db/db mice.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; bcl-2-Associated X Protein; Diabetic Nephropathie | 2014 |
[The combinations of statins and fibrates: pharmacokinetic and clinical implications].
Topics: Atherosclerosis; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fibric Ac | 2014 |
[The fixed combination of pravastatin and fenofibrate: what can it provide?].
Topics: Atherosclerosis; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hyd | 2014 |
[Efficacy studies].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hy | 2014 |
[Achievement of therapeutic objectives].
Topics: Atherosclerosis; Cardiovascular Diseases; Drug Administration Schedule; Drug Combinations; Dyslipide | 2014 |
[Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia].
Topics: Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutary | 2014 |
[Indications for the combination of pravastatin and fenofibrate according to the cardiovascular risk level. Common clinical situations].
Topics: Cardiovascular Diseases; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethy | 2014 |
[Treatment of older patients with dyslipidemia].
Topics: Age Factors; Aged; Atherosclerosis; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Re | 2014 |
Different effects of fenofibrate on metabolic and cardiovascular risk factors in mixed dyslipidemic women with normal thyroid function and subclinical hypothyroidism.
Topics: Adult; Aged; C-Reactive Protein; Cardiotoxicity; Cardiovascular Diseases; Dyslipidemias; Female; Fen | 2014 |
Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience.
Topics: Adolescent; Carbohydrates; Child; Child, Preschool; Craniopharyngioma; Dyslipidemias; Female; Fenofi | 2015 |
The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Dyslipidemias; Fenofibra | 2015 |
Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.
Topics: Atherosclerosis; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fe | 2015 |
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dysl | 2015 |
The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study.
Topics: Adult; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Drug Therapy, Combination; Dyslipidemi | 2016 |
The effect of hypolipidemic treatment on monocyte cytokine release in different age groups of patients with type 2 diabetes and atherogenic dyslipidemia.
Topics: Adult; Age Factors; Aged; Atherosclerosis; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Fema | 2016 |
[Efficacy of fenofibrate for hepatic steatosis in rats after severe burn].
Topics: Animals; Burns; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Fatty Acids; Fenofibrate; Liver; | 2016 |
Xanthomata striata palmaris regression with fenofibrate in type III dyslipoproteinemia: A clinical report.
Topics: Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents; Xanthomatosis | 2016 |
[Part III. Clinical control of fenofibrate therapy].
Topics: Cardiovascular Diseases; Contraindications; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents | 2016 |
Dyslipidaemia: Small triumph for fenofibrate therapy in dyslipidaemia.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Fenofib | 2017 |
Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia.
Topics: Animal Feed; Animals; Apolipoprotein A-V; Apolipoprotein E2; Apolipoproteins A; Atherosclerosis; Cho | 2008 |
Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet.
Topics: Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Dose-Response Relationship | 2008 |
Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results.
Topics: Apolipoprotein C-III; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholester | 2008 |
Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Drug Therapy, Combination; Dyslipidemias; Female; Fenofi | 2009 |
Fenofibric Acid (trilipix).
Topics: Coronary Disease; Drug Approval; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydr | 2009 |
Unexpected and abnormally low HDL cholesterol levels on combination hypolipidemic therapy.
Topics: Atorvastatin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; | 2009 |
Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.
Topics: Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Enzyme-Linked Immunosorbent Assay; Female; Fenofi | 2010 |
Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
Topics: Adult; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydr | 2009 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
[HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
Topics: Apolipoprotein A-I; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; | 2010 |
Paradoxical decrease in high-density lipoprotein cholesterol with fenofibrate: a quite rare phenomenon indeed.
Topics: Aged; Aged, 80 and over; Biomarkers; Cholesterol, HDL; Down-Regulation; Drug Therapy, Combination; D | 2010 |
"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Comb | 2010 |
[Treatments for cardiovascular risk factors and screening for coronary artery disease in type 2 diabetes mellitus].
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Evidence-Based Medicine; Fenofibrate; Hu | 2010 |
The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diabetes Mellitus; Dyslip | 2010 |
[Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
Topics: Aged; Atherosclerosis; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; D | 2010 |
Combination lipid therapy in type 2 diabetes.
Topics: Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidem | 2010 |
Activation of peroxisome proliferator-activated receptor α in megakaryocytes reduces platelet-derived growth factor-BB in platelets.
Topics: Adult; Becaplermin; Blood Platelets; Cell Differentiation; Cell Line, Tumor; Dyslipidemias; Female; | 2011 |
Retinopathy progression in type 2 diabetes.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Drug Therapy | 2010 |
Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model.
Topics: Animals; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipi | 2011 |
Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status.
Topics: Adult; Aged; Apolipoprotein A-V; Apolipoproteins A; Apolipoproteins E; Cholesterol, HDL; Cholesterol | 2011 |
Therapy: HIV-associated dyslipidemia: the heart positive study.
Topics: Drug Therapy, Combination; Dyslipidemias; Exercise Therapy; Fenofibrate; Heart Diseases; HIV Infecti | 2011 |
Fibrate use in the United States and Canada.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Drug Utilization; Dyslipid | 2011 |
Fibrate use in the United States and Canada.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Utilization; Dyslipidemias; Fenofibrate; Fi | 2011 |
[A dyslipidemia animal model induced by poloxamer 407 in golden hamsters and pilot study on the mechanism].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; CD36 Antigens; Cricetinae; Disease Models, Animal; | 2011 |
Fibrates in the treatment of dyslipidemias--time for a reassessment.
Topics: Advisory Committees; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2011 |
Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
Topics: Cohort Studies; Databases, Factual; Drug Therapy, Combination; Dyslipidemias; Electronic Health Reco | 2011 |
Long-term fenofibrate treatment impaired glucose-stimulated insulin secretion and up-regulated pancreatic NF-kappa B and iNOS expression in monosodium glutamate-induced obese rats: is that a latent disadvantage?
Topics: Adenosine Triphosphatases; Animals; Blood Glucose; Dyslipidemias; Fenofibrate; Glucose; Homeostasis; | 2011 |
Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia.
Topics: Adipocytes; Adipokines; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; C | 2011 |
AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.
Topics: Animals; Benzoates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dyslipidemias; Femal | 2012 |
Managing dyslipidaemia: evolving role of combination therapy.
Topics: Atorvastatin; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoi | 2011 |
Diabetes: Should we use fibrates in patients with diabetes and mild CKD?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic | 2012 |
Clustering by plasma lipoprotein profile reveals two distinct subgroups with positive lipid response to fenofibrate therapy.
Topics: Cluster Analysis; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Lipoproteins; Ma | 2012 |
Delayed-type hypersensitivity to fenofibrate.
Topics: Aged; Bezafibrate; Cross Reactions; Drug Hypersensitivity; Dyslipidemias; Emergency Medical Services | 2012 |
A neutral risk on the development of new-onset diabetes mellitus (NODM) in Taiwanese patients with dyslipidaemia treated with fibrates.
Topics: Adult; Diabetes Complications; Diabetes Mellitus; Dyslipidemias; Female; Fenofibrate; Gemfibrozil; H | 2012 |
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Topics: Animals; Apolipoprotein E2; Apolipoproteins E; Atherosclerosis; Blood Glucose; Disease Models, Anima | 2005 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Aci | 2005 |
[Rhabdomyolysis induced by fenofibrate monotherapy].
Topics: Diabetes Mellitus; Drug Interactions; Dyslipidemias; Fenofibrate; Follow-Up Studies; Gliclazide; Hum | 2006 |
Fenofibrate lowers lipid parameters in obese dogs.
Topics: Animals; Body Weight; Dog Diseases; Dogs; Dyslipidemias; Female; Fenofibrate; Hypolipidemic Agents; | 2006 |
Should we dismiss fibrates for the treatment of diabetic dyslipidaemia?
Topics: Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; H | 2006 |
Intensive statin treatment or combination therapy in high-risk patients.
Topics: Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase I | 2007 |
[Expediency of the use of fibrates for primary and secondary prevention of cardiovascular complications.].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Fibric Acids; Humans | 2006 |
[The effect of treatment with fenofibrate on the risk profile of patients with metabolic syndrome and mixed dyslipidemia treated on an outpatient basis].
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Cholest | 2007 |
Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARalpha.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fatty Liver; Fen | 2007 |
The role of fenofibrate in clinical practice.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination | 2007 |
Diabetic retinopathy: treatment and prevention.
Topics: Combined Modality Therapy; Diabetic Retinopathy; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic A | 2007 |
Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fenofibrat | 2008 |
Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.
Topics: Diabetes Mellitus; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylgluta | 2008 |